


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:48Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406663" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406663</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>aac</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="iso-abbrev">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">aac</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406663</article-id><article-id pub-id-type="pmcid-ver">PMC12406663.1</article-id><article-id pub-id-type="pmcaid">12406663</article-id><article-id pub-id-type="pmcaiid">12406663</article-id><article-id pub-id-type="pmid">40757818</article-id><article-id pub-id-type="doi">10.1128/aac.00320-25</article-id><article-id pub-id-type="publisher-id">aac00320-25</article-id><article-id pub-id-type="publisher-id">aac.00320-25</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Mechanisms of Resistance</subject></subj-group><subj-group subj-group-type="biological-terms"><compound-subject><compound-subject-part content-type="code">antimicrobial-chemotherapy</compound-subject-part><compound-subject-part content-type="label">Antimicrobial Chemotherapy</compound-subject-part></compound-subject></subj-group></article-categories><title-group><article-title>Inhibition of efflux pumps by FDA-approved drugs oxiconazole and sertaconazole restores antibiotic susceptibility in multidrug-resistant <italic toggle="yes">S. aureus</italic></article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0439-5065</contrib-id><name name-style="western"><surname>Ojha</surname><given-names initials="S">Suvendu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names initials="P">Puja</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3352-4508</contrib-id><name name-style="western"><surname>Beuria</surname><given-names initials="TK">Tushar Kant</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review and editing</role><email>tkbeuria@ils.res.in</email></contrib><aff id="aff1"><label>1</label><institution-wrap><institution>Department of Infectious Disease Biology, Institute of Life Sciences</institution><institution-id institution-id-type="ringgold">29722</institution-id><institution-id institution-id-type="ror">https://ror.org/00x1rrc95</institution-id></institution-wrap>, <city>Bhubaneswar</city>, <state>Odisha</state>, <country>India</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution>Regional Centre for Biotechnology</institution><institution-id institution-id-type="ringgold">214253</institution-id><institution-id institution-id-type="ror">https://ror.org/00nc5f834</institution-id></institution-wrap>, <city>Faridabad</city>, <state>Haryana</state>, <country>India</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><role>Editor</role><name name-style="western"><surname>Howden</surname><given-names initials="BP">Benjamin P.</given-names></name><aff><institution-wrap><institution>The Peter Doherty Institute for Infection and Immunity</institution></institution-wrap>, <city>Melbourne</city>, <state>Victoria</state>, <country>Australia</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Address correspondence to Tushar Kant Beuria, <email xlink:href="mailto:tkbeuria@ils.res.in">tkbeuria@ils.res.in</email></corresp><fn fn-type="COI-statement"><p>A patent application is currently under process at the Indian Patent Office, registered under S.O. and T.K.B. The other author declares no conflict of interest.</p></fn></author-notes><pub-date publication-format="electronic" date-type="collection"><month>9</month><year>2025</year></pub-date><pub-date date-type="pub" publication-format="electronic"><day>04</day><month>8</month><year>2025</year></pub-date><volume>69</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">496152</issue-id><elocation-id>e00320-25</elocation-id><history><date date-type="received"><day>24</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>03</day><month>6</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Ojha et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Ojha et al.</copyright-holder><ali:free_to_read start_date="2025-08-04"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International license</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="aac.00320-25.pdf"/><self-uri content-type="pdf" xlink:href="aac.00320-25.pdf"/><abstract abstract-type="primary"><title>ABSTRACT</title><p>Antibiotic resistance in <italic toggle="yes">Staphylococcus aureus</italic> causes major concern worldwide. In <italic toggle="yes">S. aureus</italic>, efflux pumps are mostly responsible for the development of multidrug resistance. Active removal of antibiotics from cells by <italic toggle="yes">S. aureus</italic> efflux pumps, including NorA, NorB, AbcA, and MepA, helps to lower their intracellular concentration and effectiveness. The present study examined two FDA-approved antifungal medications, oxiconazole and sertaconazole, as possible efflux pump inhibitors (EPIs) against multidrug-resistant <italic toggle="yes">S. aureus</italic>. Our results showed that both drugs reduced the efflux pump activity of drug-susceptible (ATCC25923) and multidrug-resistant (Mu50) <italic toggle="yes">S. aureus</italic> strains. While sertaconazole inhibited the efflux pumps without changing the efflux rate, oxiconazole lowered both efflux pump activity and efflux rate. Neither of these drugs impacted bacterial membrane integrity nor bacterial growth. Both drugs enhanced the efficacy of norfloxacin, cefotaxime, and moxifloxacin by lowering the MIC values and showed minimal cytotoxicity toward mammalian cells. In combination with the antibiotics, both sertaconazole and oxiconazole significantly lowered the bacterial load in a murine skin infection model. Our results suggested that the drugs altered the proton motive force (PMF), which resulted in diminished membrane potential (&#916;<italic toggle="yes">&#936;</italic>) and an increased electrochemical gradient (&#916;pH), thereby inhibiting ATP production and efflux pump activity. The safety profile and potential to enhance antibiotic efficacy suggest that sertaconazole and oxiconazole may be used as EPIs for combating multidrug-resistant <italic toggle="yes">S. aureus</italic> infections. Further studies are required to assess their pharmacokinetics, toxicity, and activity against a wide range of <italic toggle="yes">S. aureus</italic> isolates.</p></abstract><kwd-group><title>KEYWORDS</title><kwd>efflux pump</kwd><kwd>EPI</kwd><kwd><italic toggle="yes">S. aureus</italic></kwd><kwd>multidrug resistance</kwd><kwd>sertaconazole</kwd><kwd>oxiconazole</kwd><kwd>MRSA</kwd><kwd>PMF inhibitor</kwd></kwd-group><funding-group specific-use="FundRef"><award-group award-type="grant" id="award-1"><funding-source><institution-wrap><institution>Department of Science and Technology, Ministry of Science and Technology, India</institution><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001409</institution-id></institution-wrap></funding-source><award-id>CRG/2021/005069</award-id><principal-award-recipient><name name-style="western"><surname>Beuria</surname><given-names>Tushar Kant</given-names></name></principal-award-recipient></award-group></funding-group><counts><count count="1" count-type="supplementary-material"/><count count-type="authors" count="3"/><fig-count count="7"/><table-count count="2"/><equation-count count="3"/><ref-count count="78"/><page-count count="20"/><word-count count="11095"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>INTRODUCTION</title><p><italic toggle="yes">Staphylococcus aureus</italic>, a gram-positive bacterium, poses a significant public health concern due to its widespread presence and ability to cause various infections (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Estimates suggest that approximately 50% of adults are either permanent or intermittent carriers of <italic toggle="yes">S. aureus</italic>, highlighting the organism&#8217;s widespread presence in the human population (<xref rid="B3" ref-type="bibr">3</xref>). <italic toggle="yes">S. aureus</italic> can cause various infections like impetigo, folliculitis, infected wounds, and bacteremia, potentially resulting in critical conditions like sepsis (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). One of the most concerning developments in <italic toggle="yes">S. aureus</italic> epidemiology is the emergence and spread of methicillin-resistant <italic toggle="yes">S. aureus</italic> (MRSA) strains due to overuse of antibiotics. MRSA strains often show multidrug resistance, complicating effective treatment with conventional antibiotics and emphasizing the necessity for an effective medical approach to address this public health issue (<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">&#8211;</xref><xref rid="B7" ref-type="bibr">7</xref>).</p><p>Bacteria have developed various methods to resist the effects of antibiotics, allowing them to survive in the presence of antibiotics. One such method is to enhance the expression or activity of efflux pumps to remove antibiotics from the cell to decrease the intracellular concentration of antibiotics, resulting in a multidrug-resistant phenotype (<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">&#8211;</xref><xref rid="B11" ref-type="bibr">11</xref>). Efflux pumps in bacteria are classified into five primary categories: the ATP-Binding Cassette (ABC) superfamily, the Major Facilitator Superfamily (MFS), the Resistance-Nodulation-Division (RND) family, the Small Multidrug Resistance (SMR) family, and the Multidrug and Toxic Compound Extrusion (MATE) family. The ABC superfamily uses energy from ATP hydrolysis to facilitate substrate efflux, while the MFS, SMR, and RND superfamilies utilize the proton motive force (PMF), and the MATE superfamily utilizes sodium gradients as its energy source (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). The electrochemical gradient (&#916;pH) and the electric or membrane potential (&#916;<italic toggle="yes">&#936;</italic>) constitute the proton motive force (PMF) in bacteria. The unequal distribution of H<sup>+</sup> ions across the bacterial membrane produces the &#916;pH, whereas the unequal distribution of other ions, including K<sup>+</sup>, Cl&#8315;, and Na<sup>+</sup>, across the bacterial membrane contributes to the membrane potential (&#916;<italic toggle="yes">&#936;</italic>). The bacterial ATP synthase utilizes the energy produced by the unequal distribution of H<sup>+</sup> ions across the bacterial membrane to produce ATP (<xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">&#8211;</xref><xref rid="B20" ref-type="bibr">20</xref>).</p><p>The primary efflux pumps identified in <italic toggle="yes">S. aureus</italic> include NorA, NorB, QacA, and QacB, which are classified under the MFS type. Additionally, AbcA, Sav1866, and MsrA are categorized as ABC types, while MepA is associated with the MATE type, and Smr is part of the SMR family (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B22" ref-type="bibr">22</xref>). The resistance of <italic toggle="yes">S. aureus</italic> to fluoroquinolones (norfloxacin and moxifloxacin) is typically driven by the overexpression of NorA and NorB efflux pumps, while the resistance to cephalosporins (cefotaxime) is associated with the overexpression of AbcA efflux pumps (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B23" ref-type="bibr">23</xref>). The efflux-mediated resistance can be prevented by efflux pump inhibitors (EPIs) through (a) modifying gene regulation to decrease the expression of efflux genes, (b) changing the structure of antibiotics so they are not recognized as substrates, (c) preventing the assembly of the efflux pumps, (d) inhibiting the binding of substrates to the efflux pumps, and (e) inhibiting the energy source necessary for the efflux pump. Since EPIs inhibit the efflux pumps, they can enhance the efficacy of antibiotics by increasing cytoplasmic retention and potentially be used as adjuvants (<xref rid="B24" ref-type="bibr">24</xref><xref rid="B25" ref-type="bibr">&#8211;</xref><xref rid="B28" ref-type="bibr">28</xref>).</p><p>EPIs against <italic toggle="yes">S. aureus</italic> have been identified from both natural and synthetic origins. For example, plant-derived EPIs, such as reserpine, curcumin, silibinin, coumarins, etc. (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>), and synthetic molecules such as 4-acetyl-3-(4-fluorophenyl)-1-(p-tolyl)-5-methylpyrrole, N-trans-3,4-O-dimethylcaffeoyl tryptamine, etc., inhibit the NorA efflux pump (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Furthermore, the plant-derived EPI Clerodane diterpene 16&#945;-hydroxycleroda-3,13 (14)-Z-dien-15,16-olide inhibits the NorB, NorC, MepA, and MdeA efflux pumps. Linoleic and oleic acids inhibit the MsrA efflux pump; &#945;-terpinene blocks the TetK efflux pump. Likewise, synthetic EPIs such as 10-(4-(-3-phenylureido)-benzylamino)-9-fluoro-3,7-dihydro-3-methyl-7-oxo-2H-[1,4]oxazino[2,3,4-ij]-Quinoline-6-carboxylic acid (Q6CA) inhibits both the NorA and MepA efflux pumps, whereas cholecalciferol and alpha-tocopherol inhibit the TetK and MsrA efflux pumps (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). However, none of these EPIs have reached successful commercialization, mostly because of their high cytotoxicity and the complexities associated with their synthesis (<xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Furthermore, in recent times, to address the challenges of natural and synthetic EPIs, FDA-approved drugs have been repurposed as EPIs. Drugs such as nilotinib, diclofenac sodium, domperidone, and glyceryl trinitrate have been identified as EPIs against <italic toggle="yes">S. aureus</italic>, specifically targeting the NorA efflux pump. While these EPIs show promise, their action is limited primarily to NorA, and their potency is suboptimal, exhibiting only moderate inhibition of efflux pumps (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B31" ref-type="bibr">31</xref><xref rid="B32" ref-type="bibr">&#8211;</xref><xref rid="B33" ref-type="bibr">33</xref>). The current study reveals two FDA-approved antifungal drugs, sertaconazole and oxiconazole, as effective EPIs against <italic toggle="yes">S. aureus</italic>. Both EPIs exhibited minimal cytotoxicity toward mammalian cells and synergistically improved the efficacy of antibiotics significantly against multidrug-resistant <italic toggle="yes">S. aureus</italic> infections in both <italic toggle="yes">in vitro</italic> and murine skin infection models. The findings further indicated that sertaconazole and oxiconazole inhibited efflux pumps by disrupting the energy necessary for their activity.</p></sec><sec sec-type="materials|methods" id="s2"><title>MATERIALS AND METHODS</title><sec id="s2-1"><title>Materials</title><p>Ethidium bromide (EtBr, Product Number E1510), chlorpromazine (CPZ, Product Number C8138), thioridazine (TZ, Product Number 1662504), glucose (glu, Product Number G8644), and cefotaxime sodium (Cefo, Product Number 1097909) from Sigma-Aldrich. Norfloxacin (Nor, Item No. 25975), moxifloxacin (Mox, Item No. 14830), sertaconazole nitrate (Sert, Item No. 22232), and oxiconazole nitrate (Oxi, Item No. 18724) were purchased from Cayman Chemicals. Tryptone soya agar (TSA, Catalogue No. M1968), tryptone soya broth (TSB, Catalogue No. M011), antibiotic E-strips, and mannitol salt agar (MSA, Catalogue No. MH118) were obtained from Himedia. Additionally, the Bacterial Membrane Potential Assay Kit (Catalogue Number: B349500) and the Live-Dead Assay Kit (Catalogue Number: L7012) were received from Invitrogen.</p></sec><sec id="s2-2"><title>Bacterial strains, plasmids, and culture conditions</title><p>The bacterial strains studied are methicillin-sensitive <italic toggle="yes">Staphylococcus aureus </italic>subsp<italic toggle="yes">. aureus </italic>Rosenbach (MSSA, ATCC25923) and multidrug-resistant <italic toggle="yes">Staphylococcus aureus </italic>subsp<italic toggle="yes">. aureus </italic>strain Mu50 (NRS1, ATCC700699). The cells were grown in a TSB medium at 37&#176;C and 200 rpm. The bacterial growth phase was determined by changes in optical density at 600 nm (OD<sub>600</sub>) using a Shimadzu spectrophotometer.</p></sec><sec id="s2-3"><title>Ethidium bromide accumulation assay</title><p>As previously described, fluorometry was used to measure the accumulation of EtBr in both the ATCC25923 and Mu50-ATCC700699 strains (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). The bacterial strains were cultured until OD<sub>600</sub> ~ 0.6. Subsequently, the cells were centrifuged and resuspended to an OD<sub>600</sub> ~ 0.3 using phosphate-buffered saline (PBS), pH 7.4. The OD-adjusted cells were seeded in a 96-well black plate. EtBr at 1 &#181;g/mL was added to all experimental groups, while sertaconazole and oxiconazole were used at a final concentration of 10 &#181;M (~4.9 &#181;g/mL). TZ, a recognized efflux pump inhibitor, was used at half MIC concentration (16 &#181;g/mL). At the same time, glucose (0.4%) was used as a negative control due to its role in enhancing efflux activity. All treatments were performed simultaneously during the addition of EtBr. Finally, fluorescence intensity (FI) changes were measured at 37&#176;C and 200 rpm for 1 h at 5 min intervals in a VictorNivo multimode plate reader (PerkinElmer, RRID: SCR_025763). The FI was measured at an excitation wavelength of 530 nm and an emission wavelength of 585 nm. The OD<sub>600</sub> adjusted fluorescence intensity at 60 min was chosen for the calculations of EtBr accumulation.</p></sec><sec id="s2-4"><title>Ethidium bromide efflux assay</title><p>The effects of sertaconazole and oxiconazole on EtBr efflux were examined in both ATCC25923 and Mu50 using a fluorimeter, as previously described (<xref rid="B34" ref-type="bibr">34</xref><xref rid="B35" ref-type="bibr">&#8211;</xref><xref rid="B36" ref-type="bibr">36</xref>). In an approach similar to the EtBr accumulation assay, the OD-adjusted cells (OD<sub>600</sub> ~ 0.3) were subjected to incubation with EtBr (1 &#181;g/mL) together with sertaconazole (10 &#181;M), oxiconazole (10 &#181;M), CPZ (16 &#181;g/mL), and TZ (16 &#181;g/mL) across various experimental groups for 1 h at 37&#176;C and 200 rpm. Following a 1 h incubation period to activate the efflux, the cells were treated with 0.4% glucose. The glucose-treated cells were then assessed for changes in FI at 530 nm excitation and 585 nm emission wavelengths at 5 min intervals for 1 h using a VictorNivo multimode plate reader. The OD-adjusted FI of cells at 60 min was selected to calculate EtBr efflux.</p></sec><sec id="s2-5"><title>Bacterial susceptibility testing</title><p>Following the guidelines established by the Clinical and Laboratory Standards Institute (CLSI) (<xref rid="B37" ref-type="bibr">37</xref>) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (<xref rid="B38" ref-type="bibr">38</xref>), the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the antibiotics (norfloxacin, moxifloxacin, and cefotaxime), sertaconazole, and oxiconazole were assessed using the broth microdilution method using a previously standardized protocol (<xref rid="B39" ref-type="bibr">39</xref>). Briefly, bacterial cells were cultured to an OD<sub>600</sub> ~ 1; working concentrations of the antibiotics, sertaconazole and oxiconazole, were prepared at 256 &#181;g/mL in TSB media. Using the serial dilution method, a concentration range of 128&#8211;0.125 &#181;g/mL was prepared from the working concentration in a 96-well microtiter plate (Eppendorf, Catalogue Number: CLS9017). Finally, bacterial cultures were added at a final concentration of 0.5 MacFarland standard, and the plate was incubated for 18 h at 37&#176;C and 200 rpm. After 18 h of incubation, the plates were assessed for a change in turbidity, and MIC was identified as a concentration with no turbidity. Subsequently, from the 18 h incubated plate, 3 &#181;L was inoculated onto TSA plates and incubated for 18 h at 37&#176;C to assess MBC concentration. After 18 h of incubation, plates were analyzed, and MBC was determined as the concentration with no bacterial colonies (<xref rid="B39" ref-type="bibr">39</xref>).</p></sec><sec id="s2-6"><title>Synergy assay</title><p>The potential synergistic interaction between sertaconazole and oxiconazole to increase the <italic toggle="yes">in vitro</italic> effectiveness of existing antibiotics (norfloxacin, moxifloxacin, and cefotaxime) against ATCC25923 and Mu50 was studied using the previously mentioned checkerboard synergy assay with modifications (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). Bacterial cells were cultured until OD<sub>600</sub> ~ 1. Working concentrations (10&#215; of the final required concentration) of antibiotics, sertaconazole, and oxiconazole were prepared in TSB and added onto the plate in various combinations. Bacterial cultures were added to each well at a final concentration of 0.5 MacFarland standard and incubated at 37&#176;C and 200 rpm for 18 h. The plates were analyzed after 18 h to observe the change in turbidity, and the lowest combined concentration that exhibited no turbidity was determined as the MIC in combination. The fractional inhibitory concentration (FIC) was evaluated using the MIC values obtained from susceptibility testing (MIC alone) and synergy assays (MIC in combination). The FIC was calculated as mentioned below. Where A represents antibiotics, and B represents sertaconazole or oxiconazole. The combination was assessed as synergistic when FIC &#8804; 0.5, additive when FIC &gt; 0.5 and &lt;1, indifferent when FIC &gt; 1 and &lt;4, and antagonistic when FIC &#8805; 4.</p><disp-formula id="uFD1"><alternatives><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.m001.jpg"/><mml:math id="um1" display="block" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">B</mml:mi></mml:mrow></mml:mstyle></mml:math></alternatives></disp-formula><disp-formula id="uFD2"><alternatives><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.m002.jpg"/><mml:math id="um2" display="block" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">A</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">A</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mtext>&#160;</mml:mtext><mml:mo>&#247;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">A</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></alternatives></disp-formula><disp-formula id="uFD3"><alternatives><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.m003.jpg"/><mml:math id="um3" display="block" overflow="scroll"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">B</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">B</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mtext>&#160;</mml:mtext><mml:mo>&#247;</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">M</mml:mi><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">B</mml:mi><mml:mtext>&#160;</mml:mtext><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></alternatives></disp-formula></sec><sec id="s2-7"><title>Bacterial growth curve</title><p>Following the previously described bacterial growth curve assay (<xref rid="B42" ref-type="bibr">42</xref>), we assessed the effect of sertaconazole and oxiconazole on bacterial growth. In the process of growth curve analysis, bacterial cells were cultured overnight. Subsequently, a fresh inoculum of a 0.5 McFarland standard culture was prepared in TSB by diluting the overnight culture within a 48-well microtiter plate. Sertaconazole and oxiconazole were given at various time intervals at a final concentration of 4 &#181;g/mL. The plate was observed for changes in OD<sub>600</sub> with a VictorNivo multimode plate reader every hour for 6 h, maintained at 37&#176;C and 200 rpm. The OD<sub>600</sub> readings were analyzed to observe the effect of sertaconazole and oxiconazole on bacterial growth.</p></sec><sec id="s2-8"><title>Live-dead assay and microscopy</title><p>The cell viability of bacteria was assessed using flow cytometry (BD Accuri C6 Plus, RRID: SCR_014422) and fluorescence microscopy with the LIVE/DEAD BacLight Bacterial Viability and Counting Kit. Fluorescence microscopy was conducted according to a previously standardized method (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B43" ref-type="bibr">43</xref>). Flow cytometry was performed according to the manufacturer&#8217;s protocol. Both studies used a concentration of 4 &#181;g/mL. Flow cytometry observations were recorded in logarithmic mode during acquisition and analyzed utilizing FlowJo software (RRID: SCR_008520). In flow cytometry, an unstained control was utilized to gate the target cells. In contrast, an untreated culture (ATCC25923 or Mu50) was used as the live cell control in both studies, and a culture treated with 70% ethanol (Ethanol) was used as the dead cell control. Initially, unstained cells were gated in flow cytometry based on forward scatter (FSC) and side scatter (SSC) characteristics to distinguish the target cells and eliminate any cell debris. The target cells were subsequently gated according to the fluorescence of Syto9 and PI to identify live and dead cell populations, respectively.</p></sec><sec id="s2-9"><title>Cytotoxicity assay</title><p>The MTT cell viability assay was performed according to the manufacturer&#8217;s guidelines to study the effect of sertaconazole and oxiconazole on the viability of mammalian cells, either alone or in combination with antibiotics. The study was performed on human lung cancer adherent cells (A549, RRID: CVCL_UJ49) and kidney epithelial cells (HEK293T, RRID: CVCL_0063). For the individual effect of sertaconazole or oxiconazole, the change in cell viability was assessed by comparing the absorbance at 570 nm with non-treated cells (control). For the combinatorial effect of sertaconazole or oxiconazole with antibiotics, the cell viability was assessed by comparing the absorbance at 570 nm with individually treated cells (control). The 50% cytotoxic concentration (CC<sub>50</sub>) of sertaconazole and oxiconazole was determined using absorbance values at 570 nm and plotting for &#8220;[Inhibitor] vs. normalized response variable slope&#8221; in GraphPad Prism Version 10.2.3 (RRID: SCR 002798). A combination of antibiotics and compound, showing &gt;70% viable cells, was considered not to affect cell viability (<xref rid="B44" ref-type="bibr">44</xref>).</p></sec><sec id="s2-10"><title>Murine skin infection model</title><sec id="s2-10-1"><title>Sample size calculation by power analysis</title><p>The hypothesis of the study was, &#8220;The combination of antibiotics with sertaconazole or oxiconazole yields a significantly greater reduction in multidrug-resistant <italic toggle="yes">S. aureus</italic> infection in comparison with antibiotics or drugs alone.&#8221; The sample size per group in the study was determined by power analysis using <italic toggle="yes">a priori</italic>: compute required given sample size, given <italic toggle="yes">&#945;</italic>, power, and effect size by two-tailed <italic toggle="yes">t</italic>-test for independent means of two groups in G*Power software, version 3.1.9.6 (<xref rid="B45" ref-type="bibr">45</xref>). The following parameters were used for the calculation: <italic toggle="yes">&#945;</italic> = 0.05, power (1<italic toggle="yes">&#8722;&#946;</italic>) = 0.90, allocation ratio (<italic toggle="yes">N</italic>2/<italic toggle="yes">N</italic>1) = 1, and effect size (Cohen&#8217;s <italic toggle="yes">d</italic>) = 2.35. The effect size was determined using the means and standard deviations of the two independent groups as follows: mean of group 1 (average CFU/g in the infection group): 13, standard deviation (SD) of group 1: 1.5; mean of group 2 (average CFU/g for the drug-antibiotic combination): 9, SD of group 2: 1. Based on these values, the calculated sample size (<italic toggle="yes">N</italic>) was found to be five.</p></sec><sec id="s2-10-2"><title>Animal selection</title><p>This study used female BALB/c mice selected for their beneficial behavioral and physiological characteristics. The immune response in female mice is observed to be more robust compared to that of male mice, which may be attributed to the effects of oestrogen on phagocytosis (<xref rid="B46" ref-type="bibr">46</xref>). Furthermore, females show enhanced resistance to <italic toggle="yes">S. aureus</italic> skin infections, displaying reduced severity and inflammation at the sites of infection (<xref rid="B47" ref-type="bibr">47</xref>). It is crucial to acknowledge that male mice frequently exhibit aggressive behavior, resulting in bite wounds and other skin injuries that may influence the results of the study focused on skin infections (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>).</p></sec><sec id="s2-10-3"><title>Experimental procedure</title><p>A previously described method was followed (<xref rid="B50" ref-type="bibr">50</xref>) to determine the <italic toggle="yes">in vivo</italic> efficacy of antibiotics (norfloxacin, moxifloxacin, and cefotaxime), sertaconazole, and oxiconazole, either alone or in combination, in a murine skin infection model for Mu50. Based on G power analysis, a total of 45 female BALB/c mice (6-week-old) in 9 groups, with 5 mice per experimental group in a cage, were used in the study. Before the start of the experiment, the mice were anesthetized to shave the right flank region and allowed to recover. On day 1, the mice were administered 200 &#181;L of Mu50 cells in PBS (Gibco, Catalogue number: 10010023) containing 1 &#215; 10<sup>8</sup> cells by subcutaneous injection in the shaved right flank region and were allowed to develop an infection for 2 days. From day 3 onward, treatment was administered daily in sterile PBS for 5 days. The administered treatments included sertaconazole (10 mg/kg) (<xref rid="B51" ref-type="bibr">51</xref><xref rid="B52" ref-type="bibr">&#8211;</xref><xref rid="B54" ref-type="bibr">54</xref>), oxiconazole (10 mg/kg) (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>), norfloxacin (100 mg/kg) (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>), moxifloxacin (100 mg/kg) (<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>), and cefotaxime (15 mg/kg) (<xref rid="B61" ref-type="bibr">61</xref><xref rid="B62" ref-type="bibr">&#8211;</xref><xref rid="B63" ref-type="bibr">63</xref>), either alone or in combination. On day 8, the mice were sacrificed by CO<sub>2</sub> asphyxiation, and infected skin tissues were collected for colony-forming units (CFU) plating. The tissue samples were homogenized in 1 mL of PBS, and the CFU was quantified through serial dilution of 100 &#181;L tissue samples on Mannitol Salt Agar, followed by incubation at 37&#176;C for 18 h. Every experimental setup included a control group receiving no infection. The statistical significance between various treatment groups was evaluated using one-way analysis of variance (ANOVA) with GraphPad Prism software Version 10.2.3 (RRID: SCR_002798). To ensure experimental consistency and comparability of results, the images representing control, infection, and single antibiotic treatment groups were used as internal controls in the combination therapy investigations, including either sertaconazole or oxiconazole.</p></sec><sec id="s2-10-4"><title>Membrane potential assay</title><p>The effect of sertaconazole and oxiconazole on the membrane potential of <italic toggle="yes">S. aureus</italic> (ATCC25923 &amp; Mu50) was evaluated using the Bacterial Membrane Potential Assay Kit, as previously mentioned (<xref rid="B42" ref-type="bibr">42</xref>). The kit uses a membrane-potential-sensitive dye, DiOC<sub>2</sub>, exhibiting red fluorescence in bacterial cells with unchanged or increased membrane potential. In contrast, it shows green fluorescence in depolarized cells (reduced membrane potential). Briefly, bacterial cells were cultured till OD<sub>600</sub> ~ 0.3 and were given treatment for 1 h. The studied treatment groups included sertaconazole (4 &#181;g/mL), oxiconazole (4 &#181;g/mL), and CCCP (a known protonophore) (5 &#181;M). Following 1 h of treatment, cells were centrifuged at 10,000 &#215; <italic toggle="yes">g</italic> for 5 min, washed in PBS, and resuspended in PBS to an OD<sub>600</sub> ~ 0.3. The cells were subsequently stained with 30 &#181;M DiOC&#8322; and incubated for 30 min at room temperature in the dark. Fluorescence was ultimately assessed at an excitation wavelength of 485 nm and emission wavelengths of 530 nm (green) and 610 nm (red) in the CYTOFLEX flow cytometry machine (RRID: SCR_019627). The observations were recorded in logarithmic mode and analyzed with FlowJo software. Additionally, the red/green ratio was determined using the red and green intensities acquired during flow cytometry data acquisition to assess the size-independent effect.</p></sec><sec id="s2-10-5"><title>Microbial cell viability assay</title><p>The effect of sertaconazole and oxiconazole on cellular ATP levels was assessed using the BacTiter-Glo kit (Promega, Catalog number: G8230) following the manufacturer&#8217;s protocol. Cells were cultured to an OD<sub>600</sub> ~ 0.3 and treated with 4 &#181;g/mL sertaconazole or oxiconazole for one hour at 37&#176;C and 200 rpm. CCCP, a commonly used protonophore that diminishes cellular ATP levels, was used as a positive control. Following 1 h of treatment, cells were centrifuged at 5,000 rpm for 5 min and resuspended in an equal volume of PBS. Subsequently, 50 &#181;L of resuspended cells was mixed with 50 &#181;L of BacTiter Glo reagent, and the relative luminescence unit (RLU) and OD600<sub>600</sub> were determined using the VictorNivo multimode plate reader. The RLU units were normalized with the OD<sub>600</sub> value.</p></sec><sec id="s2-10-6"><title>Ethidium bromide agar cartwheel assay</title><p>The level of efflux activity between ATCC25923 and Mu50 was evaluated by the EtBr agar cartwheel assay following the previously described method (<xref rid="B64" ref-type="bibr">64</xref>). Briefly, the ATCC25923 and Mu50 cells were cultured till OD<sub>600</sub> ~ 0.6. The TSA agar plates with different concentrations of EtBr were prepared, and then the OD<sub>600</sub> ~ 0.6 bacterial cultures were streaked onto the agar plates and incubated for 18 h at 37&#176;C. Following incubation, the plates were observed under UV light for EtBr fluorescence, where higher EtBr fluorescence indicates lesser efflux pump activity and vice versa.</p></sec></sec></sec><sec sec-type="results" id="s3"><title>RESULTS</title><sec id="s3-1"><title>Efflux pump inhibitory activity of sertaconazole and oxiconazole against <italic toggle="yes">S. aureus</italic></title><p>This study assessed the efflux pump inhibitory activity of sertaconazole and oxiconazole using EtBr accumulation and EtBr efflux assays in drug-sensitive (ATCC25923) and drug-resistant (Mu50) <italic toggle="yes">S. aureus</italic>. EtBr serves as a substrate for most efflux pumps in <italic toggle="yes">S. aureus,</italic> and both assays quantify the EtBr accumulation in relation to efflux pump activity. In the accumulation assay, increased EtBr accumulation correlates with the inhibition of efflux pumps, whereas in efflux assays, higher EtBr accumulation suggests a reduction in the glucose-mediated efflux rates. In our study, both sertaconazole (<xref rid="F1" ref-type="fig">Fig. 1A</xref>) and oxiconazole (<xref rid="F1" ref-type="fig">Fig. 1C</xref>) treatments demonstrated an increased EtBr accumulation in both strains, indicating a concentration-dependent inhibition of efflux pumps. The efflux assay demonstrated that sertaconazole (<xref rid="F1" ref-type="fig">Fig. 1B</xref>) exhibited little to no change in EtBr efflux in ATCC25923, and oxiconazole (<xref rid="F1" ref-type="fig">Fig. 1D</xref>) demonstrated decreased EtBr efflux. In contrast, both drugs showed decreased EtBr efflux in Mu50 (<xref rid="F1" ref-type="fig">Fig. 1B and D</xref>).</p><fig position="float" fig-type="figure" id="F1" orientation="portrait"><label>Fig 1</label><caption><p>Sertaconazole and oxiconazole inhibit <italic toggle="yes">S. aureus</italic> efflux pumps <italic toggle="yes">in vitro</italic>. Using ethidium bromide (EtBr) accumulation and the EtBr efflux assay, the inhibition of the efflux pump was studied. Panels A and C show bar graphs that depict the concentration-dependent increase in relative fluorescence of EtBr in the presence of sertaconazole (Sert) and oxiconazole (Oxi), respectively. Thioridazine (TZ) is a known efflux pump inhibitor, used as a positive control at 16 &#181;g/mL, while glucose (Glu), known to enhance active efflux, was used as a negative control at 0.4%. Panels B and D illustrate the decrease in EtBr efflux in the presence of sertaconazole and oxiconazole. Chlorpromazine (CPZ) and TZ, known EPIs, were used as positive controls at 16 &#181;g/mL. The data reported are an average of three individual experiments, and the significance was determined using ordinary one-way ANOVA assuming Gaussian distribution, followed by multiple comparisons with &#352;id&#225;k correction, and is reported as <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.001, <sup>&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.002, <sup>&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.033, <sup>ns</sup><italic toggle="yes">P</italic> &gt; 0.05.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.f001.jpg"><alt-text>Bar graphs depicting FI percentages in ATCC25923 and Mu50 strains treated with different concentration of sertaconazole or oxiconazole. FI increases significantly at higher concentrations, with Mu50 generally showing stronger responses than ATCC25923.</alt-text></graphic></fig></sec><sec id="s3-2"><title>Antibacterial properties of sertaconazole and oxiconazole</title><p>The potential antibacterial effect of sertaconazole and oxiconazole was examined using susceptibility testing in <italic toggle="yes">S. aureus</italic> (ATCC25923 &amp; Mu50). The results showed that sertaconazole and oxiconazole inhibited the growth of both ATCC25923 and Mu50, with MICs of 4 &#181;g/mL and 8 &#181;g/mL, respectively (<xref rid="T1" ref-type="table">Table 1</xref>). Although both compounds inhibited bacterial growth, they did not show bacterial killing activity in <italic toggle="yes">S. aureus</italic>. Our results showed a high value of MBC &gt; 128 &#181;g/mL for both the sensitive and resistant strains of <italic toggle="yes">S. aureus</italic> (<xref rid="T1" ref-type="table">Table 1</xref>). Similarly, we also determined the antibacterial effects of three other antibiotics (norfloxacin, cefotaxime, and moxifloxacin). These three antibiotics are the major substrates for the <italic toggle="yes">S. aureus</italic> efflux pumps. The MIC and MBC values are shown in <xref rid="T1" ref-type="table">Table 1</xref>. Our results showed that ATCC25923 was sensitive to cefotaxime, norfloxacin, and moxifloxacin with respective MICs of 0.5, 2, and 0.064 &#181;g/mL, whereas Mu50 was resistant to all the above antibiotics with MICs of 256, 256, and 32 &#181;g/mL, respectively.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Sertaconazole and oxiconazole susceptibility and synergistic (FIC) evaluation with antibiotic combinations in ATCC25923 and MRSA Mu50 (ATCC700699)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="top" colspan="1" rowspan="1">SI no.</th><th align="left" valign="top" colspan="1" rowspan="1">Combination</th><th align="left" valign="top" colspan="1" rowspan="1">Compound/antibiotic</th><th align="left" valign="top" colspan="1" rowspan="1">MIC alone (A)</th><th align="left" valign="top" colspan="1" rowspan="1">MBC</th><th align="left" valign="top" colspan="1" rowspan="1">MIC in combination (B)</th><th align="left" valign="top" colspan="1" rowspan="1">B/A</th><th align="left" valign="top" colspan="1" rowspan="1">FIC</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">ATCC25923</td><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;1</td><td align="left" valign="top" rowspan="2" colspan="1">Sertaconazole + cefotaxime</td><td align="left" valign="top" colspan="1" rowspan="1">Sertaconazole</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.25</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Cefotaxime</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">0.062</td><td align="left" valign="top" colspan="1" rowspan="1">0.124</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;2</td><td align="left" valign="top" rowspan="2" colspan="1">Sertaconazole + norfloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">Sertaconazole</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.38</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Norfloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">16</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.250</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;3</td><td align="left" valign="top" rowspan="2" colspan="1">Sertaconazole + moxifloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">Sertaconazole</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">1.13</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Moxifloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">0.064</td><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">0.064</td><td align="left" valign="top" colspan="1" rowspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;4</td><td align="left" valign="top" rowspan="2" colspan="1">Oxiconazole + cefotaxime</td><td align="left" valign="top" colspan="1" rowspan="1">Oxiconazole</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.23</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Cefotaxime</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">0.062</td><td align="left" valign="top" colspan="1" rowspan="1">0.124</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;5</td><td align="left" valign="top" rowspan="2" colspan="1">Oxiconazole + norfloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">Oxiconazole</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.38</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Norfloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">16</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.250</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;6</td><td align="left" valign="top" rowspan="2" colspan="1">Oxiconazole + moxifloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">Oxiconazole</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">1.13</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Moxifloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">0.064</td><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">0.064</td><td align="left" valign="top" colspan="1" rowspan="1">1.000</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Mu50</td><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/><td align="left" valign="bottom" colspan="1" rowspan="1"/></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;7</td><td align="left" valign="top" rowspan="2" colspan="1">Sertaconazole + cefotaxime</td><td align="left" valign="top" colspan="1" rowspan="1">Sertaconazole</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.19</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Cefotaxime</td><td align="left" valign="top" colspan="1" rowspan="1">256</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">16</td><td align="left" valign="top" colspan="1" rowspan="1">0.063</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;8</td><td align="left" valign="top" rowspan="2" colspan="1">Sertaconazole + norfloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">Sertaconazole</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.38</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Norfloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">256</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">64</td><td align="left" valign="top" colspan="1" rowspan="1">0.250</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;9</td><td align="left" valign="top" rowspan="2" colspan="1">Sertaconazole + moxifloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">Sertaconazole</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">0.5</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.25</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Moxifloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">32</td><td align="left" valign="top" colspan="1" rowspan="1">64</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;10</td><td align="left" valign="top" rowspan="2" colspan="1">Oxiconazole + cefotaxime</td><td align="left" valign="top" colspan="1" rowspan="1">Oxiconazole</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.25</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Cefotaxime</td><td align="left" valign="top" colspan="1" rowspan="1">256</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">32</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;11</td><td align="left" valign="top" rowspan="2" colspan="1">Oxiconazole + norfloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">Oxiconazole</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.38</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Norfloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">256</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">64</td><td align="left" valign="top" colspan="1" rowspan="1">0.250</td></tr><tr><td align="left" valign="top" rowspan="2" colspan="1">&#8195;12</td><td align="left" valign="top" rowspan="2" colspan="1">Oxiconazole + moxifloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">Oxiconazole</td><td align="left" valign="top" colspan="1" rowspan="1">8</td><td align="left" valign="top" colspan="1" rowspan="1">&gt;128</td><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td><td align="left" valign="top" rowspan="2" colspan="1">0.25</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">Moxifloxacin</td><td align="left" valign="top" colspan="1" rowspan="1">32</td><td align="left" valign="top" colspan="1" rowspan="1">64</td><td align="left" valign="top" colspan="1" rowspan="1">4</td><td align="left" valign="top" colspan="1" rowspan="1">0.125</td></tr></tbody></table></table-wrap><p>In our study, sertaconazole is used at its MIC concentration (4 &#181;g/mL); oxiconazole is used at its half-MIC concentration (4 &#181;g/mL). To assess the effects of sertaconazole and oxiconazole on bacterial growth and to examine the bacteriostatic effect of both drugs at the MIC concentration, we performed a bacterial growth curve (<xref rid="F2" ref-type="fig">Fig. 2</xref>). The growth curve analysis indicated that at the MIC concentration, both drugs inhibited <italic toggle="yes">S. aureus</italic> growth. However, the OD<sub>600</sub> values did not decline upon the addition of the drugs, indicating that both sertaconazole (<xref rid="F2" ref-type="fig">Fig. 2A and B</xref>) and oxiconazole (<xref rid="F2" ref-type="fig">Fig. 2E and F</xref>) are bacteriostatic in nature. The analysis also showed that oxiconazole at half-MIC concentration did not impact bacterial growth (<xref rid="F2" ref-type="fig">Fig. 2C and D</xref>). The susceptibility and growth curve analysis findings indicated that at the used concentration, sertaconazole inhibited bacterial growth, and oxiconazole did not affect bacterial growth.</p><fig position="float" fig-type="figure" id="F2" orientation="portrait"><label>Fig 2</label><caption><p>Effect of sertaconazole and oxiconazole on <italic toggle="yes">S. aureus</italic> growth. A bacterial growth curve assay was performed to investigate the effect of sertaconazole (Sert) and oxiconazole (Oxi) on the growth of <italic toggle="yes">S. aureus</italic> (ATCC25923 and Mu50). ATCC25923 and Mu50 were grown in tryptic soy broth, with treatments given hourly using Sert at a concentration of 4 &#181;g/mL (MIC) or Oxi at concentrations of either 4 &#181;g/mL (1/2 MIC) or 8 &#181;g/mL (MIC). The growth of ATCC25923 and Mu50 was monitored for 6 h by measuring the optical density (OD) at 600 nm at hourly intervals. Panels A and B illustrate that Sert at 4 &#181;g/mL effectively inhibits the growth of ATCC25923 and Mu50, respectively, suggesting a bacteriostatic effect. Panels C and D illustrate that Oxi at 4 &#181;g/mL does not affect the growth of ATCC25923 and Mu50, respectively. At a concentration of 8 &#181;g/mL, Oxi demonstrates bacteriostatic effects by markedly suppressing the growth of ATCC25923 (panel E) and Mu50 (panel F).</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.f002.jpg"><alt-text>Line graphs depicting OD600 over six hours for MSSA and Mu50 treated with sertaconazole or oxiconazole at different timepoints. Sertaconazole inhibits MSSA and Mu50 growth at both 4 and 8 &#956;g/mL, whereas oxiconazole inhibits growth only at 8 &#956;g/mL.</alt-text></graphic></fig></sec><sec id="s3-3"><title>Sertaconazole and oxiconazole synergistically enhanced the antibacterial effectiveness of existing antibiotics</title><p>A checkerboard synergy assay was used to investigate the possible effects of sertaconazole and oxiconazole in combination with cefotaxime, norfloxacin, or moxifloxacin on enhancing their efficacy against <italic toggle="yes">S. aureus</italic> (ATCC25923 &amp; Mu50). The MICs of antibiotics (norfloxacin, cefotaxime, and moxifloxacin) and EPIs (sertaconazole and oxiconazole), alone or in combination, were determined against <italic toggle="yes">S. aureus</italic>. The FIC values were calculated as specified in the method section and used to determine possible combinatorial effects. The FIC values &lt; 0.5 indicate synergistic effects, whereas values between 0.5 &gt; FIC &lt; 1 show additive effects, and higher values indicate indifferent (1 &gt; FIC &lt; 4) or antagonistic effects (FIC &gt; 4) (<xref rid="T1" ref-type="table">Table 1</xref>). In ATCC25923, both EPIs demonstrated to be synergistic (FIC &lt; 0.5) with norfloxacin and cefotaxime, while they showed indifference in combination with moxifloxacin (FIC 1.13) (<xref rid="F3" ref-type="fig">Fig. 3</xref>; <xref rid="T1" ref-type="table">Table 1</xref>). In Mu50, both EPIs demonstrated synergy with all three antibiotics (<xref rid="F3" ref-type="fig">Fig. 3</xref>; <xref rid="T1" ref-type="table">Table 1</xref>). The indifference effect of moxifloxacin in combination with sertaconazole or oxiconazole may result from reduced efflux pump activity in ATCC25923, as illustrated in <xref rid="SuF1" ref-type="supplementary-material">Fig. S2</xref>, where increased EtBr fluorescence signifies diminished EtBr efflux and enhanced EtBr accumulation, and vice versa.</p><fig position="float" fig-type="figure" id="F3" orientation="portrait"><label>Fig 3</label><caption><p>Oxiconazole and sertaconazole act in synergy with antibiotics. Using the checkerboard synergy assay, the combinatorial effects of sertaconazole and oxiconazole with antibiotics were studied. The figure illustrates a heat map depicting the <italic toggle="yes">in vitro</italic> synergistic effects of different concentrations of sertaconazole (Sert) and oxiconazole (Oxi) in combination with norfloxacin, moxifloxacin, and cefotaxime against ATCC25923 and Mu50.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.f003.jpg"><alt-text>Heatmap depicting FIC indices for cefotaxime, norfloxacin and moxifloxacin combined with sertaconazole or oxiconazole against ATCC25923 and Mu50. Synergy observed for all drugs except moxifloxacin with ATCC25923, which shows indifference.</alt-text></graphic></fig></sec><sec id="s3-4"><title>Sertaconazole and oxiconazole did not affect bacterial membrane integrity</title><p>Sertaconazole and oxiconazole are known to disrupt membrane integrity as antifungal agents (<xref rid="B65" ref-type="bibr">65</xref>). Thus, to assess if sertaconazole and oxiconazole have similar effects on the membrane integrity of <italic toggle="yes">S. aureus</italic>, we evaluated the cell viability using a live-dead assay (Syto9-PI staining) by both flow cytometry and fluorescence microscopy. Untreated cells (ATCC25923 and Mu50) served as the live cell controls and showed a whole green population, whereas cells treated with 70% ethanol were used as the dead cell controls and showed a whole red population. The fluorescence microscopy analysis (<xref rid="F4" ref-type="fig">Fig. 4A and B</xref>) showed that <italic toggle="yes">S. aureus,</italic> when treated for 1 h with sertaconazole and oxiconazole at 4 &#181;g/mL, had no effects on the bacterial membrane. The cell behavior was similar to that of untreated cells, with most of the cell population being live and intact. The percentage of viable cells, determined using ImageJ analysis of microscopic images, showed &gt;98% viable cells in both sertaconazole and oxiconazole treatments (<xref rid="F4" ref-type="fig">Fig. 4C and D</xref>). Additionally, we assessed the percentage of viable cells using flow cytometry (<xref rid="F4" ref-type="fig">Fig. 4E</xref>), which also demonstrated a similar pattern, showing &gt;98% viable cells upon sertaconazole and oxiconazole treatments. The results indicated that sertaconazole and oxiconazole treatment did not affect bacterial membrane integrity.</p><fig position="float" fig-type="figure" id="F4" orientation="portrait"><label>Fig 4</label><caption><p>Effect of sertaconazole and oxiconazole on the bacterial membrane. Using a live-dead assay, the effects of sertaconazole and oxiconazole were studied. Panels A and B demonstrate that neither sertaconazole nor oxiconazole affects the bacterial membrane, with over 98% of viable cells at 4 &#181;g/mL for ATCC25923 and Mu50, respectively. Panels C and D show the bar plot illustrating the percentage of live and dead cell counts in the presence of 4 &#181;g/mL of sertaconazole (Sert) and oxiconazole (Oxi) in both ATCC25923 and Mu50 strains, respectively. The cell number was quantified from microscopic images utilizing ImageJ software. Panel E represents flow cytometry analysis indicating that neither sertaconazole nor oxiconazole affects bacterial membranes, with over 98% of viable cells at 4 &#181;g/mL for ATCC25923 and Mu50, respectively. The entire study used 70% ethanol-treated cells as a dead cell control (stained with PI), whereas untreated cells (ATCC25923 &amp; Mu50) were used as the live cell control (stained with Syto9).</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.f004.jpg"><alt-text>Composite figure depicting MSSA and Mu50 viability after treatment. Fluorescence microscopy shows mostly live cells after oxiconazole or sertaconazole treatment, similar to untreated, unlike ethanol. Bar graphs and flow plots confirm findings.</alt-text></graphic></fig></sec><sec id="s3-5"><title>Sertaconazole and oxiconazole showed lower toxicity toward mammalian cells</title><p>To determine the effect of sertaconazole and oxiconazole on mammalian cell viability, we performed an MTT assay using A549 lung cancer adherent cells and HEK293T epithelial cells. The cell viability indicated that most of the cell population was viable at 8 &#181;M (4 &#181;g/mL) for both sertaconazole and oxiconazole (<xref rid="T2" ref-type="table">Table 2</xref>), the concentration used in our experiment. The 50% cytotoxic concentration (CC<sub>50</sub>) was determined to be 23.5 &#177; 5.3 &#181;M and 24.5 &#177; 2.9 &#181;M for sertaconazole and oxiconazole, respectively, in A549 cells (<xref rid="T2" ref-type="table">Table 2</xref>). For HEK293T, the CC<sub>50</sub> was calculated to be 9.9 &#177; 2.2 &#181;M and 17.9 &#177; 1.1 &#181;M for sertaconazole and oxiconazole, respectively (<xref rid="T2" ref-type="table">Table 2</xref>). Additionally, we assessed the potential effects of combining sertaconazole or oxiconazole with antibiotics (norfloxacin, moxifloxacin, and cefotaxime) on the viability of A549 mammalian cells. Our results showed that combining 10 &#181;M antibiotics with 10 &#181;M of either sertaconazole or oxiconazole had minimal effects on cell viability (<xref rid="SuF1" ref-type="supplementary-material">Fig. S1</xref>). The cell viability analysis suggested that at the experimental concentrations, both sertaconazole and oxiconazole have minimal impact on mammalian cell viability, individually, or in combination with antibiotics.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Evaluation of 50% cytotoxicity (CC<sub>50</sub>) of sertaconazole and oxiconazole in mammalian cells</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col span="1"/><col span="1"/><col span="1"/><col span="1"/></colgroup><thead><tr><th align="left" valign="bottom" rowspan="2" colspan="1">SI no.</th><th align="left" valign="bottom" rowspan="2" colspan="1">Drug</th><th align="center" valign="bottom" colspan="2" rowspan="1">CC<sub>50</sub> (&#956;M) for:</th></tr><tr><th align="left" valign="bottom" colspan="1" rowspan="1">A549</th><th align="left" valign="bottom" colspan="1" rowspan="1">HEK293T</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="1" rowspan="1">1</td><td align="left" valign="top" colspan="1" rowspan="1">Sertaconazole</td><td align="left" valign="top" colspan="1" rowspan="1">23.5 &#177; 5.3</td><td align="left" valign="top" colspan="1" rowspan="1">9.9 &#177; 2.2</td></tr><tr><td align="left" valign="top" colspan="1" rowspan="1">2</td><td align="left" valign="top" colspan="1" rowspan="1">Oxiconazole</td><td align="left" valign="top" colspan="1" rowspan="1">24.5 &#177; 2.9</td><td align="left" valign="top" colspan="1" rowspan="1">17.9 &#177; 1.1</td></tr></tbody></table></table-wrap></sec><sec id="s3-6"><title>Sertaconazole and oxiconazole enhanced the efficacy of the antibiotics against <italic toggle="yes">S. aureus</italic> in a murine skin infection model</title><p>Our <italic toggle="yes">in vitro</italic> synergistic analysis demonstrated an increased efficacy of antibiotics against ATCC25923 and Mu50 when combined with sertaconazole or oxiconazole. We evaluated the combinatorial effects in a murine skin infection model to determine if the combinations can improve antibiotic efficiency <italic toggle="yes">in vivo</italic>. Briefly, Mu50 was subcutaneously administered in the right flank region of female Balb/C mice and incubated for 2 days to develop the infection. On day 3, the treatment of sertaconazole (10 mg/kg), oxiconazole (10 mg/kg), norfloxacin (100 mg/kg), moxifloxacin (100 mg/kg), and cefotaxime (15 mg/kg) were administered daily for 5 days, either individually or in combination. On day 8, mice were sacrificed, and the infected skin tissue (<xref rid="SuF1" ref-type="supplementary-material">Fig. S3A</xref>) was collected for viable cell counting (CFU plating). The results showed that individual administration of sertaconazole, oxiconazole, and antibiotics was ineffective in reducing Mu50 infection, showing &#8804;1 log<sub>10</sub> reduction in the CFU count (<xref rid="F5" ref-type="fig">Fig. 5B and D</xref>). In contrast, combining sertaconazole or oxiconazole with antibiotics showed higher efficacy than the individual treatments (<xref rid="F5" ref-type="fig">Fig. 5A through D</xref>). Sertaconazole showed the highest efficacy when combined with norfloxacin (4.4 log<sub>10</sub> reduction in CFU count) or cefotaxime (3.4 log<sub>10</sub> reduction in CFU count) (<xref rid="F5" ref-type="fig">Fig. 5B</xref>). Additionally, in combination with moxifloxacin, sertaconazole showed a 2 log<sub>10</sub> reduction in viable cell count (<xref rid="F5" ref-type="fig">Fig. 5B</xref>). Meanwhile, oxiconazole showed the highest efficacy when combined with cefotaxime (5.4 log<sub>10</sub> reduction) and moxifloxacin (4.6 log<sub>10</sub> reduction) (<xref rid="F5" ref-type="fig">Fig. 5D</xref>). Similarly, in combination with norfloxacin, oxiconazole showed a 2 log<sub>10</sub> reduction in viable cell count (<xref rid="F5" ref-type="fig">Fig. 5D</xref>). The weight of the mice remained unchanged during the entire study (<xref rid="SuF1" ref-type="supplementary-material">Fig. S3B</xref>). The mouse study showed that sertaconazole and oxiconazole enhanced the efficacy of the antibiotics similar to that observed for <italic toggle="yes">in vitro</italic> studies (<xref rid="F3" ref-type="fig">Fig. 3</xref>).</p><fig position="float" fig-type="figure" id="F5" orientation="portrait"><label>Fig 5</label><caption><p><italic toggle="yes">In vivo</italic> efficacy of antibiotics with sertaconazole or oxiconazole. The effectiveness of antibiotics in combination with sertaconazole (Sert) or oxiconazole (Oxi) against <italic toggle="yes">S. aureus</italic> Mu50 were assessed in a mouse model. Panels A and C show images of the infected and treated skin areas on day 1 of treatment (day 3) and the day of sacrifice (day 8). Panels B and D illustrate the bacterial load in the skin tissues of uninfected mice (Control), Mu50-infected mice (Infection), and those treated with antibiotics, sertaconazole, and oxiconazole on day 8. The bacterial load was assessed using the viable cell count method and represented as log10 CFU/g. Nor, norfloxacin; Mox, moxifloxacin; Cefo, cefotaxime. The significance was determined using ordinary one-way ANOVA assuming Gaussian distribution, followed by multiple comparisons with &#352;id&#225;k correction, and is reported as <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.001, <sup>&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.002, <sup>&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.033, <sup>ns</sup><italic toggle="yes">P</italic> &gt; 0.05. The control, infection, and individual antibiotic treatment groups (Nor, Mox, and Cefo) are common for both sertaconazole and oxiconazole combination treatments; therefore, the images representing these groups are the same in panels A &amp; C and B &amp; D.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.f005.jpg"><alt-text>Composite figure depicting infected lesion sites at day 3 and day 8 under different treatments, with corresponding bar graphs comparing log cfu per gram. Combination therapies reduce bacterial load more effectively than monotherapies.</alt-text></graphic></fig></sec><sec id="s3-7"><title>Sertaconazole and oxiconazole reduced membrane potential and inhibited ATP production</title><p>The primary energy sources for efflux pump function in <italic toggle="yes">S. aureus</italic> are proton motive force (PMF), which includes both alterations in transmembrane proton gradient, also known as the electrochemical gradient (&#916;pH), and electric or membrane potential (&#916;<italic toggle="yes">&#936;</italic>) (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B14" ref-type="bibr">14</xref><xref rid="B15" ref-type="bibr">&#8211;</xref><xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Thus, to determine whether sertaconazole and oxiconazole inhibit the efflux pump activity of <italic toggle="yes">S. aureus</italic> (ATCC25923 &amp; Mu50) by altering membrane potential and ATP production, we investigated their effects on bacterial membrane potential and ATP production. The effect on bacterial membrane potential was evaluated by flow cytometry using the BacLight bacterial membrane potential kit (Invitrogen), which utilizes DiOC<sub>2</sub>, a membrane potential-sensitive dye. DiOC<sub>2</sub> shows red fluorescence in cells with unaltered membrane potential and green fluorescence in depolarized cells (decreased membrane potential). CCCP, a known protonophore that depolarizes bacterial membranes, was a positive control for our experiment (<xref rid="B20" ref-type="bibr">20</xref>). The flow cytometry results (<xref rid="F6" ref-type="fig">Fig. 6A</xref>) showed that both sertaconazole and oxiconazole decreased the membrane potential of <italic toggle="yes">S. aureus</italic>. Most of the <italic toggle="yes">S. aureus</italic> treated with sertaconazole or oxiconazole showed higher green intensity than red intensity and showed a cellular pattern similar to that of CCCP-treated cells (<xref rid="F6" ref-type="fig">Fig. 6A</xref>). It is previously known that bacterial size can influence the outcome of the potential study (<xref rid="B66" ref-type="bibr">66</xref>). Thus, we also checked the red-to-green intensity ratio (<xref rid="F6" ref-type="fig">Fig. 6B</xref>) to see the effect of sertaconazole and oxiconazole on bacterial membrane potential and the dependence on bacterial size. Both sertaconazole and oxiconazole showed a reduced red/green ratio similar to that seen with CCCP-treated cells in both ATCC25923 and Mu50 (<xref rid="F6" ref-type="fig">Fig. 6B</xref>). This further supported the reduction of the membrane potential of <italic toggle="yes">S. aureus</italic> by both sertaconazole and oxiconazole, which is independent of the cell size.</p><fig position="float" fig-type="figure" id="F6" orientation="portrait"><label>Fig 6</label><caption><p>Sertaconazole and oxiconazole induce depolarization and decrease ATP levels in <italic toggle="yes">S. aureus</italic>. The membrane potential of ATCC25923 and Mu50 was assessed in the presence of sertaconazole (Sert) and oxiconazole (Oxi) at a concentration of 4 &#181;g/mL using DiOC<sub>2</sub> labeling and flow cytometry. The protonophore CCCP is a positive control in both experiments due to its known ability to depolarize bacteria and reduce ATP production. Untreated cells (ATCC25923 &amp; Mu50) serve as controls in both experiments, demonstrating no alteration in membrane potential or ATP production. In Panel A, the red color indicates no alteration in membrane potential, while the green color indicates membrane depolarization. Panel A demonstrates that sertaconazole and oxiconazole result in depolarization in both ATCC25923 and Mu50, exhibiting a cellular pattern similar to that of CCCP-treated cells in flow cytometry. Panel B illustrates the relative red-to-green fluorescence intensity ratio in cells treated with sertaconazole, oxiconazole, and CCCP. Panel C demonstrates that treatment with 4 &#181;g/mL of either sertaconazole or oxiconazole has effects similar to CCCP, showing a reduction in relative luminescence units (RLU) compared to the control, indicating reduced ATP production in both ATCC25923 and Mu50 cells. Panel D illustrates the relative ATP production of ATCC25923 cells following treatment with either 4 &#181;g/mL sertaconazole or oxiconazole. Panel E illustrates the relative ATP production in Mu50 cells following treatment with either 4 &#181;g/mL sertaconazole or oxiconazole. The relative ATP production was measured using the ATP standard curve (<xref rid="SuF1" ref-type="supplementary-material">Fig. S4</xref>). The data reported are from three individual experiments, and the significance was determined using ordinary two-way ANOVA assuming Gaussian distribution, followed by multiple comparisons with &#352;id&#225;k correction, and is reported as <sup>&#8727;&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.001, <sup>&#8727;&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.002, <sup>&#8727;</sup><italic toggle="yes">P</italic> &lt; 0.033, <sup>ns</sup><italic toggle="yes">P</italic> &gt;0.05.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.f006.jpg"/></fig><p>Studies have shown that a reduction in the membrane potential alters the proton motive force, leading to the reduction in ATP production in bacteria (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B66" ref-type="bibr">66</xref>). To find out if treatment with sertaconazole or oxiconazole could reduce ATP production, we determined the ATP production by assessing bacterial cell viability using the BacTiter-Glo Microbial Cell Viability Assay kit (Promega), which determines viable bacterial cells by measuring total ATP production; a higher number of viable cells will indicate increased ATP production and vice versa. As CCCP is known to reduce membrane potential and reduce ATP production, we used CCCP as a positive control to observe the reduction in ATP production (<xref rid="B20" ref-type="bibr">20</xref>). Our results showed that both sertaconazole and oxiconazole reduced bacterial ATP production, similar to CCCP in ATCC25923 and Mu50 (<xref rid="F6" ref-type="fig">Fig. 6C</xref>). Additionally, we quantified the ATP production of ATCC25923 and Mu50 at a concentration of 4 &#181;g/mL of either sertaconazole or oxiconazole, utilizing the ATP standard curve (<xref rid="SuF1" ref-type="supplementary-material">Fig. S4</xref>). The analysis of ATCC25923 indicated that untreated cells (ATCC25923) generated 13.2 &#177; 1.1 &#181;M ATP (<xref rid="F6" ref-type="fig">Fig. 6D</xref>). In contrast, cells treated with sertaconazole and oxiconazole showed decreased ATP production, yielding 9 &#177; 1.1 &#181;M and 9 &#177; 0.61 &#181;M ATP, respectively, displaying an identical response to CCCP (8.9 &#177; 0.4 &#181;M) (<xref rid="F6" ref-type="fig">Fig. 6D</xref>). In Mu50, the study indicated that untreated cells (Mu50) generated 3.8 &#177; 0.2 &#181;M ATP (<xref rid="F6" ref-type="fig">Fig. 6E</xref>). In contrast, cells treated with sertaconazole and oxiconazole showed reduced ATP production, yielding 3 &#177; 0.2 &#181;M and 3.1 &#177; 0.15 &#181;M ATP, respectively, demonstrating an equivalent response to CCCP (2.8 &#177; 0.28 &#181;M) (<xref rid="F6" ref-type="fig">Fig. 6E</xref>). The analysis of bacterial membrane potential and ATP production showed that sertaconazole and oxiconazole reduce <italic toggle="yes">S. aureus</italic> membrane potential, resulting in the disruption of PMF, which leads to reduced ATP production. In <italic toggle="yes">S. aureus,</italic> PMF and ATP serve as the energy sources for efflux pump activity, and the results showed that sertaconazole and oxiconazole disrupt PMF and reduce ATP production, suggesting that both drugs inhibit efflux pumps in <italic toggle="yes">S. aureus</italic> by hampering the energy required for the efflux pump activity.</p></sec></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>Antibiotic resistance seriously compromises public health worldwide. This is particularly true for many drug-resistant bacteria, such as <italic toggle="yes">S. aureus</italic>. Even with the availability of potent antimicrobials, the mortality rate associated with <italic toggle="yes">S. aureus</italic> bacteremia continues to be alarmingly high, ranging from 20% to 40% (<xref rid="B67" ref-type="bibr">67</xref>). Efflux pumps are essential for multidrug resistance development in <italic toggle="yes">S. aureus</italic>. They systematically eliminate a range of antibiotics and other antimicrobials from the bacterial cells (<xref rid="B10" ref-type="bibr">10</xref>). They also play crucial roles in removing endogenous metabolites, releasing virulence factors, and during cellular responses to stress (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B68" ref-type="bibr">68</xref>). In <italic toggle="yes">S. aureus</italic>, several multidrug efflux pumps have been identified, including NorA, NorB, AbcA, and MepA, which remove a range of antibiotics and dyes, such as fluoroquinolones, cefotaxime, and ethidium bromide (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B13" ref-type="bibr">13</xref>). Thus, inhibition of these pumps is a potential approach for restoring the effectiveness of antibiotics against multidrug-resistant <italic toggle="yes">S. aureus</italic>.</p><p>This study demonstrates that sertaconazole and oxiconazole, both FDA-approved antifungal agents, serve as effective EPIs against multidrug-resistant <italic toggle="yes">S. aureus</italic>. Both drugs significantly reduced the function of efflux pumps in the drug-sensitive ATCC25923 and the multidrug-resistant Mu50 strains. Both drugs resulted in a significant increase in EtBr accumulation, which serves as a standard assay for assessing efflux pump activity, thereby demonstrating their effectiveness in inhibiting efflux pumps in <italic toggle="yes">S. aureus</italic>. Sertaconazole demonstrated inhibition of efflux pumps (<xref rid="F1" ref-type="fig">Fig. 1A</xref>) while maintaining the efflux rate (<xref rid="F1" ref-type="fig">Fig. 1B</xref>). In contrast, oxiconazole not only inhibited efflux pumps (<xref rid="F1" ref-type="fig">Fig. 1C</xref>) but also decreased the efflux rate (<xref rid="F1" ref-type="fig">Fig. 1D</xref>). Both drugs demonstrated bacteriostatic activity (<xref rid="F2" ref-type="fig">Fig. 2</xref>) with no impact on bacterial membrane integrity or growth (<xref rid="F2 F4" ref-type="fig">Fig. 2 and 4</xref>).</p><p>An essential characteristic of an ideal EPI is its ability to enhance the effectiveness of existing antibiotics while maintaining low toxicity levels for mammalian cells (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>). The findings of our study indicated that sertaconazole and oxiconazole improved the antibacterial efficacy of norfloxacin and cefotaxime against ATCC25923 and Mu50 (<xref rid="F3" ref-type="fig">Fig. 3</xref>; <xref rid="T1" ref-type="table">Table 1</xref>). Additionally, both drugs improved the effectiveness of moxifloxacin against Mu50, showing no variation in efficacy against ATCC25923 (<xref rid="F3" ref-type="fig">Fig. 3</xref>; <xref rid="T1" ref-type="table">Table 1</xref>). This could be attributed to the differential expression of efflux pumps between the two strains, with ATCC25923 having fewer active efflux pumps (<xref rid="SuF1" ref-type="supplementary-material">Fig. S2</xref>). Furthermore, the cytotoxicity of both drugs was assessed in mammalian cells (A549 and HEK293T), revealing that both exhibited low cytotoxicity (<xref rid="T2" ref-type="table">Table 2</xref>), thus presenting them as safe for potential combination therapies. Additionally, the combination of these drugs with antibiotics demonstrated minimal cytotoxicity toward mammalian cells (<xref rid="SuF1" ref-type="supplementary-material">Fig. S1</xref>), strengthening their potential for therapeutic application.</p><p><italic toggle="yes">In vivo</italic> studies using a murine skin infection model of <italic toggle="yes">S. aureus</italic> infection provided additional confirmation of the improved antibacterial efficacy of antibiotics when combined with sertaconazole or oxiconazole. The combination treatment demonstrated a significant reduction in bacterial burden compared to antibiotics or drugs alone. Sertaconazole demonstrated a higher level of synergy with norfloxacin (<xref rid="F5" ref-type="fig">Fig. 5B</xref>), whereas oxiconazole increased the effectiveness of moxifloxacin and cefotaxime in combination (<xref rid="F5" ref-type="fig">Fig. 5D</xref>). The combination of sertaconazole or oxiconazole with antibiotics led to a significant reduction in <italic toggle="yes">S. aureus</italic> infection, highlighting their potential as adjuvants to the current antibiotic treatments in the fight against multidrug-resistant <italic toggle="yes">S. aureus</italic> infections.</p><p>The mechanism of action of sertaconazole and oxiconazole as EPIs was elucidated by examining their effect on the PMF of <italic toggle="yes">S. aureus</italic>. Both drugs caused depolarization of the bacterial membrane (<xref rid="F6" ref-type="fig">Fig. 6A and B</xref>), resulting in a reduction in electric or membrane potential (&#916;<italic toggle="yes">&#936;</italic>) and an increase in the electrochemical gradient (&#916;pH), hence disrupting cellular ATP production (<xref rid="F6" ref-type="fig">Fig. 6C through E</xref>). By interrupting the PMF and ATP production, both drugs reduced the activity of MFS-type and ABC-type efflux pumps, resulting in enhanced intracellular antibiotic retention and higher antibiotic effectiveness in combination with these drugs (<xref rid="F7" ref-type="fig">Fig. 7</xref>).</p><fig position="float" fig-type="figure" id="F7" orientation="portrait"><label>Fig 7</label><caption><p>Mechanism of efflux pump inhibition by sertaconazole or oxiconazole. In <italic toggle="yes">S. aureus</italic>, proton motive force (PMF) provides the energy essential for the functioning of MFS-type efflux pumps, which mostly efflux fluoroquinolones. Simultaneously, the ATP synthase in the bacterial membrane uses the PMF to produce ATP, which is then used by an ABC-type efflux pump to efflux cephalosporins. Sertaconazole or oxiconazole treatment disrupts the PMF. Disruption of PMF leads to inhibition of MFS-type efflux pumps, resulting in decreased efflux and increased cytoplasmic accumulation of fluoroquinolone. Furthermore, PMF disruption also leads to inhibition of ATP synthesis, which results in inhibition of ABC-type efflux pumps, resulting in decreased efflux and increased cytoplasmic accumulation of cephalosporins. The figure was created in <ext-link xlink:href="https://BioRender.com" ext-link-type="uri">BioRender.com</ext-link>.</p></caption><graphic position="float" orientation="portrait" xlink:href="aac.00320-25.f007.jpg"><alt-text>Side-by-side schematic depicting untreated and treated S. aureus cells. Sertaconazole or oxiconazole disrupts proton motive force, inhibits ATP synthase and ABC transporters, blocks fluoroquinolone and cephalosporin efflux, enhancing drug retention.</alt-text></graphic></fig><p>Evaluating sertaconazole and oxiconazole alongside previously identified EPIs, including both plant-derived and synthetic EPIs, offers more understanding of their potential therapeutic efficacy. For example, plant-derived EPIs such as berberine, curcumin, and resveratrol have shown modest EPI efficacy against <italic toggle="yes">S. aureus</italic> (<xref rid="B69" ref-type="bibr">69</xref><xref rid="B70" ref-type="bibr">&#8211;</xref><xref rid="B71" ref-type="bibr">71</xref>). Although these compounds have potential as EPIs, their limited bioavailability and high toxicity restrict their practical application (<xref rid="B26" ref-type="bibr">26</xref>). In contrast, the FDA-approved sertaconazole and oxiconazole, as topical antifungal drugs, provide enhanced safety due to minimal systemic exposure, therefore mitigating the risks associated with poor bioavailability and high toxicity (<xref rid="B72" ref-type="bibr">72</xref><xref rid="B73" ref-type="bibr">&#8211;</xref><xref rid="B78" ref-type="bibr">78</xref>). Sertaconazole and oxiconazole also outperform several synthetic and peptide-based EPIs. Synthetic EPIs such as phenylalanine-arginine-&#946;-naphthylamide (PA&#946;N), verapamil, and carbonyl cyanide m-chlorophenylhydrazone (CCCP) exhibit significant efflux inhibition but possess high toxicity and low solubility (<xref rid="B26" ref-type="bibr">26</xref>). Therefore, with FDA approval, strong efflux inhibition activity, and the capacity to increase the efficacy of antibiotics in combination against multidrug-resistant <italic toggle="yes">S. aureus</italic> while exhibiting minimal toxicity to mammalian cells, both sertaconazole and oxiconazole represent strong viable options for clinical development as EPIs for tackling antimicrobial resistance in <italic toggle="yes">S. aureus</italic>.</p><p>Although the results are promising, there are certain limitations to consider. First, our investigation focused on a limited number of <italic toggle="yes">S. aureus</italic> strains; further research should assess the effectiveness of sertaconazole and oxiconazole against a wider array of clinical isolates to ascertain the generalizability of the results. Second, while our <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> investigations demonstrated enhanced antibacterial efficacy of antibiotics when combined with sertaconazole or oxiconazole against multidrug-resistant <italic toggle="yes">S. aureus</italic>, additional pharmacokinetic and toxicological studies are necessary to evaluate clinical applicability, especially in combination with the antibiotics. Additionally, further research is needed to elucidate the molecular mechanisms through which these drugs inhibit efflux pumps and modulate PMF, thereby improving their potential in combination therapies.</p><p>In summary, sertaconazole and oxiconazole are promising candidates for repurposing as EPIs in the treatment of multidrug-resistant <italic toggle="yes">S. aureus</italic>. The established safety profiles, low toxicity, and capacity to enhance the efficacy of antibiotics render both drugs superior compared to various synthetic and plant-derived EPIs. More research should be conducted to optimize their pharmacokinetic properties and their efficacy when used with a broad range of antibiotics to counteract the rising threat of multidrug-resistant <italic toggle="yes">S. aureus</italic>.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We thank the imaging core facility, the flow cytometry core facility, and the animal house facility of the Institute of Life Sciences for their help.</p><p>The study was supported by funding to T.K.B. by the Department of Science and Technology, Govt. of India, Science &amp; Engineering Research Board (SERB), India [CRG/2021/005069], and core funding from the Institute of Life Sciences. S.O. is a CSIR senior research fellow, and P.C. is a DBT senior research fellow.</p><p>S.O. and T.K.B., conceptualization; S.O., microbial, biochemical, and animal work; P.C., microscopy; S.O. and T.K.B., data analysis and manuscript writing; T.K.B., supervision and funding acquisition.</p></ack><sec sec-type="data-availability" id="s5-1"><title>DATA AVAILABILITY</title><p>Any data included in the main text or supplemental material that demonstrate the study&#8217;s conclusions will be accessible upon reasonable request to the corresponding author (tkbeuria@ils.res.in). Requests for reanalysis of the data contained in this article for the purposes of replicating results will be granted. Requests for analyses beyond the scope of this publication will be evaluated by the corresponding author to evaluate the scientific and ethical appropriateness of the proposed data use.</p></sec><sec sec-type="ethics" id="s5-2"><title>ETHICS APPROVAL</title><p>Approval (ILS/IAEC-217-352 AH/APR-21) for the mouse work was obtained from the Animal Ethics Committee of the BRIC Institute of Life Sciences (BRIC-ILS), Bhubaneswar, Odisha, India.</p></sec><sec sec-type="supplementary-material" id="s5-3"><title>SUPPLEMENTAL MATERIAL</title><p specific-use="print-only">The following material is available online at <ext-link xlink:href="https://doi.org/10.1128/aac.00320-25" ext-link-type="uri">https://doi.org/10.1128/aac.00320-25</ext-link>.</p><supplementary-material id="SuF1" position="float" content-type="local-data" orientation="portrait"><object-id pub-id-type="doi">10.1128/aac.00320-25.SuF1</object-id><label>Supplemental material</label><caption><title>aac.00320-25-s0001.docx</title><p>Fig. S1 to S4.</p></caption><media xlink:href="aac.00320-25-s0001.docx" position="float" orientation="portrait"/></supplementary-material><p specific-use="online-only">ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse. </p></sec><ref-list><title>REFERENCES</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miller</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>JS</given-names></string-name></person-group>. <year>2011</year>. <article-title>Immunity against Staphylococcus aureus cutaneous infections</article-title>. <source>Nat Rev Immunol</source><volume>11</volume>:<fpage>505</fpage>&#8211;<lpage>518</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri3010</pub-id><pub-id pub-id-type="pmid">21720387</pub-id><pub-id pub-id-type="pmcid">PMC5868361</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tong</surname><given-names>SYC</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Eichenberger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Holland</surname><given-names>TL</given-names></string-name>, <string-name name-style="western"><surname>Fowler</surname><given-names>VG</given-names></string-name></person-group>. <year>2015</year>. <article-title>Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management</article-title>. <source>Clin Microbiol Rev</source><volume>28</volume>:<fpage>603</fpage>&#8211;<lpage>661</lpage>. doi:<pub-id pub-id-type="doi">10.1128/CMR.00134-14</pub-id><pub-id pub-id-type="pmid">26016486</pub-id><pub-id pub-id-type="pmcid">PMC4451395</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pantosti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Venditti</surname><given-names>M</given-names></string-name></person-group>. <year>2009</year>. <article-title>What is MRSA?</article-title><source>Eur Respir J</source><volume>34</volume>:<fpage>1190</fpage>&#8211;<lpage>1196</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00007709</pub-id><pub-id pub-id-type="pmid">19880619</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Diekema</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Pfaller</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Shortridge</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zervos</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>RN</given-names></string-name></person-group>. <year>2019</year>. <article-title>Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY antimicrobial surveillance program</article-title>. <source>Open Forum Infect Dis</source><volume>6</volume>:<fpage>S47</fpage>&#8211;<lpage>S53</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ofid/ofy270</pub-id><pub-id pub-id-type="pmid">30895214</pub-id><pub-id pub-id-type="pmcid">PMC6419894</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Augustin</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Anton-Erxleben</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Jungnickel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hemmrich</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Spudy</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Podschun</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bosch</surname><given-names>TCG</given-names></string-name></person-group>. <year>2009</year>. <article-title>Activity of the novel peptide arminin against multiresistant human pathogens shows the considerable potential of phylogenetically ancient organisms as drug sources</article-title>. <source>Antimicrob Agents Chemother</source><volume>53</volume>:<fpage>5245</fpage>&#8211;<lpage>5250</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00826-09</pub-id><pub-id pub-id-type="pmid">19770277</pub-id><pub-id pub-id-type="pmcid">PMC2786370</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Masimen</surname><given-names>MAA</given-names></string-name>, <string-name name-style="western"><surname>Harun</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Maulidiani</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ismail</surname><given-names>WIW</given-names></string-name></person-group>. <year>2022</year>. <article-title>Overcoming Methicillin-Resistance Staphylococcus aureus (MRSA) using antimicrobial peptides-silver nanoparticles</article-title>. <source>Antibiotics (Basel)</source><volume>11</volume>:<elocation-id>951</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics11070951</pub-id><pub-id pub-id-type="pmid">35884205</pub-id><pub-id pub-id-type="pmcid">PMC9311968</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Gnanamani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hariharan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Paul- Satyaseela</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Gnanamani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hariharan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Paul- Satyaseela</surname><given-names>M</given-names></string-name></person-group>. <year>2017</year>. <part-title><italic toggle="yes">Staphylococcus aureus</italic>: overview of bacteriology, clinical diseases, epidemiology, antibiotic resistance and therapeutic approach</part-title>. In <source>Frontiers in Staphylococcus aureus</source></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Varela</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Stephen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lekshmi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ojha</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wenzel</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Sanford</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Hernandez</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Parvathi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>SH</given-names></string-name></person-group>. <year>2021</year>. <article-title>Bacterial resistance to antimicrobial agents</article-title>. <source>Antibiotics (Basel)</source><volume>10</volume>:<elocation-id>593</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics10050593</pub-id><pub-id pub-id-type="pmid">34067579</pub-id><pub-id pub-id-type="pmcid">PMC8157006</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kandi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Kandi</surname><given-names>S</given-names></string-name></person-group>. <year>2015</year>. <article-title>Antimicrobial properties of nanomolecules: potential candidates as antibiotics in the era of multi-drug resistance</article-title>. <source>Epidemiol Health</source><volume>37</volume>:<elocation-id>e2015020</elocation-id>. doi:<pub-id pub-id-type="doi">10.4178/epih/e2015020</pub-id><pub-id pub-id-type="pmid">25968114</pub-id><pub-id pub-id-type="pmcid">PMC4459197</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Costa</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Viveiros</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Amaral</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Couto</surname><given-names>I</given-names></string-name></person-group>. <year>2013</year>. <article-title>Multidrug efflux pumps in Staphylococcus aureus: an update</article-title>. <source>Open Microbiol J</source><volume>7</volume>:<fpage>59</fpage>&#8211;<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1874285801307010059</pub-id><pub-id pub-id-type="pmid">23569469</pub-id><pub-id pub-id-type="pmcid">PMC3617543</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kapoor</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Saigal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Elongavan</surname><given-names>A</given-names></string-name></person-group>. <year>2017</year>. <article-title>Action and resistance mechanisms of antibiotics: a guide for clinicians</article-title>. <source>J Anaesthesiol Clin Pharmacol</source><volume>33</volume>:<fpage>300</fpage>&#8211;<lpage>305</lpage>. doi:<pub-id pub-id-type="doi">10.4103/joacp.JOACP_349_15</pub-id><pub-id pub-id-type="pmid">29109626</pub-id><pub-id pub-id-type="pmcid">PMC5672523</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Farhat</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bonomo</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>AU</given-names></string-name></person-group>. <year>2020</year>. <article-title>Efflux pumps as interventions to control infection caused by drug-resistance bacteria</article-title>. <source>Drug Discov Today</source><volume>25</volume>:<fpage>2307</fpage>&#8211;<lpage>2316</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drudis.2020.09.028</pub-id><pub-id pub-id-type="pmid">33011344</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lekshmi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stephen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ojha</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Varela</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lekshmi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stephen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ojha</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Varela</surname><given-names>M</given-names></string-name></person-group>. <year>2022</year>. <article-title>Staphylococcus aureus antimicrobial efflux pumps and their inhibitors: recent developments</article-title>. <source>AIMS Med Sci</source><volume>9</volume>:<fpage>367</fpage>&#8211;<lpage>393</lpage>. doi:<pub-id pub-id-type="doi">10.3934/medsci.2022018</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name></person-group>. <year>2023</year>. <article-title>Bacterial proton motive force as an unprecedented target to control antimicrobial resistance</article-title>. <source>Med Res Rev</source><volume>43</volume>:<fpage>1068</fpage>&#8211;<lpage>1090</lpage>. doi:<pub-id pub-id-type="doi">10.1002/med.21946</pub-id><pub-id pub-id-type="pmid">36896761</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Benarroch</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Asally</surname><given-names>M</given-names></string-name></person-group>. <year>2020</year>. <article-title>The microbiologist&#8217;s guide to membrane potential dynamics</article-title>. <source>Trends Microbiol</source><volume>28</volume>:<fpage>304</fpage>&#8211;<lpage>314</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tim.2019.12.008</pub-id><pub-id pub-id-type="pmid">31952908</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Biquet-Bisquert</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Carrio</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>TFD</given-names></string-name>, <string-name name-style="western"><surname>Abkarian</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Seduk</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Magalon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nord</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Pedaci</surname><given-names>F</given-names></string-name></person-group>. <year>2024</year>. <article-title>Spatiotemporal dynamics of the proton motive force on single bacterial cells</article-title>. <source>Sci Adv</source><volume>10</volume>:<elocation-id>eadl5849</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/sciadv.adl5849</pub-id><pub-id pub-id-type="pmid">38781330</pub-id><pub-id pub-id-type="pmcid">PMC11114223</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname><given-names>EWC</given-names></string-name>, <string-name name-style="western"><surname>Wan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>M-Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>S</given-names></string-name></person-group>. <year>2021</year>. <article-title>Active maintenance of proton motive force mediates starvation-induced bacterial antibiotic tolerance in Escherichia coli</article-title>. <source>Commun Biol</source><volume>4</volume>:<elocation-id>1068</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s42003-021-02612-1</pub-id><pub-id pub-id-type="pmid">34521984</pub-id><pub-id pub-id-type="pmcid">PMC8440630</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nelson</surname><given-names>N</given-names></string-name></person-group>. <year>1988</year>. <article-title>Structure, function, and evolution of proton-ATPases</article-title>. <source>Plant Physiol</source><volume>86</volume>:<fpage>1</fpage>&#8211;<lpage>3</lpage>. doi:<pub-id pub-id-type="doi">10.1104/pp.86.1.1</pub-id><pub-id pub-id-type="pmid">16665845</pub-id><pub-id pub-id-type="pmcid">PMC1054414</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Futai</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tsuchiya</surname><given-names>T</given-names></string-name></person-group>. <year>1987</year>. <part-title>Proton transport and proton-motive force in prokaryotic cells</part-title>, <comment>p</comment><fpage>3</fpage>&#8211;<lpage>83</lpage>. In <source>Ion transport in prokaryotes</source></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Strahl</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hamoen</surname><given-names>LW</given-names></string-name></person-group>. <year>2010</year>. <article-title>Membrane potential is important for bacterial cell division</article-title>. <source>Proc Natl Acad Sci USA</source><volume>107</volume>:<fpage>12281</fpage>&#8211;<lpage>12286</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1005485107</pub-id><pub-id pub-id-type="pmid">20566861</pub-id><pub-id pub-id-type="pmcid">PMC2901462</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sinha</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Aggarwal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>DV</given-names></string-name></person-group>. <year>2024</year>. <article-title>Efflux pumps: gatekeepers of antibiotic resistance in Staphylococcus aureus biofilms</article-title>. <source>Microb Cell</source><volume>11</volume>:<fpage>368</fpage>&#8211;<lpage>377</lpage>. doi:<pub-id pub-id-type="doi">10.15698/mic2024.11.839</pub-id><pub-id pub-id-type="pmid">39568862</pub-id><pub-id pub-id-type="pmcid">PMC11576857</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaatz</surname><given-names>GW</given-names></string-name></person-group>. <year>2002</year>. <article-title>Inhibition of bacterial efflux pumps: a new strategy to combat increasing antimicrobial agent resistance</article-title>. <source>Expert Opin Emerg Drugs</source><volume>7</volume>:<fpage>223</fpage>&#8211;<lpage>233</lpage>. doi:<pub-id pub-id-type="doi">10.1517/14728214.7.2.223</pub-id><pub-id pub-id-type="pmid">15989546</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lekshmi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ammini</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Adjei</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sanford</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Shrestha</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Varela</surname><given-names>MF</given-names></string-name></person-group>. <year>2018</year>. <article-title>Modulation of antimicrobial efflux pumps of the major facilitator superfamily in Staphylococcus aureus</article-title>. <source>AIMS Microbiol</source><volume>4</volume>:<fpage>1</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.3934/microbiol.2018.1.1</pub-id><pub-id pub-id-type="pmid">31294201</pub-id><pub-id pub-id-type="pmcid">PMC6605029</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name></person-group>. <year>2024</year>. <article-title>Bacterial efflux pump inhibitors reduce antibiotic resistance</article-title>. <source>Pharmaceutics</source><volume>16</volume>:<elocation-id>170</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/pharmaceutics16020170</pub-id><pub-id pub-id-type="pmid">38399231</pub-id><pub-id pub-id-type="pmcid">PMC10892612</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Van Bambeke</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Pag&#232;s</surname><given-names>J-M</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>VJ</given-names></string-name></person-group>. <year>2006</year>. <article-title>Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux</article-title>. <source>Recent Pat Antiinfect Drug Discov</source><volume>1</volume>:<fpage>157</fpage>&#8211;<lpage>175</lpage>. doi:<pub-id pub-id-type="doi">10.2174/157489106777452692</pub-id><pub-id pub-id-type="pmid">18221142</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sharma</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>VK</given-names></string-name>, <string-name name-style="western"><surname>Pathania</surname><given-names>R</given-names></string-name></person-group>. <year>2019</year>. <article-title>Efflux pump inhibitors for bacterial pathogens: from bench to bedside</article-title>. <source>Indian J Med Res</source><volume>149</volume>:<fpage>129</fpage>&#8211;<lpage>145</lpage>. doi:<pub-id pub-id-type="doi">10.4103/ijmr.IJMR_2079_17</pub-id><pub-id pub-id-type="pmid">31219077</pub-id><pub-id pub-id-type="pmcid">PMC6563736</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zack</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Sorenson</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>SG</given-names></string-name></person-group>. <year>2024</year>. <article-title>Types and mechanisms of efflux pump systems and the potential of efflux pump inhibitors in the restoration of antimicrobial susceptibility, with a special reference to Acinetobacter baumannii</article-title>. <source>Pathogens</source><volume>13</volume>:<elocation-id>197</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/pathogens13030197</pub-id><pub-id pub-id-type="pmid">38535540</pub-id><pub-id pub-id-type="pmcid">PMC10974122</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>AlMatar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Albarri</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Makky</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>K&#246;ksal</surname><given-names>F</given-names></string-name></person-group>. <year>2021</year>. <article-title>Efflux pump inhibitors: new updates</article-title>. <source>Pharmacol Rep</source><volume>73</volume>:<fpage>1</fpage>&#8211;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s43440-020-00160-9</pub-id><pub-id pub-id-type="pmid">32946075</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thakur</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Uniyal</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tiwari</surname><given-names>V</given-names></string-name></person-group>. <year>2021</year>. <article-title>A comprehensive review on pharmacology of efflux pumps and their inhibitors in antibiotic resistance</article-title>. <source>Eur J Pharmacol</source><volume>903</volume>:<fpage>174151</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174151</pub-id><pub-id pub-id-type="pmid">33964293</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dashtbani-Roozbehani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>MH</given-names></string-name></person-group>. <year>2021</year>. <article-title>Efflux pump mediated antimicrobial resistance by staphylococci in health-related environments: challenges and the quest for inhibition</article-title>. <source>Antibiotics (Basel)</source><volume>10</volume>:<elocation-id>1502</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics10121502</pub-id><pub-id pub-id-type="pmid">34943714</pub-id><pub-id pub-id-type="pmcid">PMC8698293</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zimmermann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Klinger-Strobel</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bohnert</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Wendler</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>R&#246;del</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Pletz</surname><given-names>MW</given-names></string-name>, <string-name name-style="western"><surname>L&#246;ffler</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Tuchscherr</surname><given-names>L</given-names></string-name></person-group>. <year>2019</year>. <article-title>Clinically approved drugs inhibit the Staphylococcus aureus multidrug NorA efflux pump and reduce biofilm formation</article-title>. <source>Front Microbiol</source><volume>10</volume>:<elocation-id>2762</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fmicb.2019.02762</pub-id><pub-id pub-id-type="pmid">31849901</pub-id><pub-id pub-id-type="pmcid">PMC6901667</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mahey</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tambat</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chandal</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Verma</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Thakur</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Nandanwar</surname><given-names>H</given-names></string-name></person-group>. <year>2021</year>. <article-title>Repurposing approved drugs as fluoroquinolone potentiators to overcome efflux pump resistance in Staphylococcus aureus</article-title>. <source>Microbiol Spectr</source><volume>9</volume>:<elocation-id>e0095121</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/Spectrum.00951-21</pub-id><pub-id pub-id-type="pmid">34908453</pub-id><pub-id pub-id-type="pmcid">PMC8672906</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abdel-Karim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>El-Ganiny</surname><given-names>AMA</given-names></string-name>, <string-name name-style="western"><surname>El-Sayed</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Abbas</surname><given-names>HAA</given-names></string-name></person-group>. <year>2022</year>. <article-title>Promising FDA-approved drugs with efflux pump inhibitory activities against clinical isolates of Staphylococcus aureus</article-title>. <source>PLoS One</source><volume>17</volume>:<elocation-id>e0272417</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0272417</pub-id><pub-id pub-id-type="pmid">35905077</pub-id><pub-id pub-id-type="pmcid">PMC9337675</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Blair</surname><given-names>JMA</given-names></string-name>, <string-name name-style="western"><surname>Piddock</surname><given-names>LJV</given-names></string-name></person-group>. <year>2016</year>. <article-title>How to measure export via bacterial multidrug resistance efflux pumps</article-title>. <source>mBio</source><volume>7</volume>:<elocation-id>e00840-16</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/mBio.00840-16</pub-id><pub-id pub-id-type="pmid">27381291</pub-id><pub-id pub-id-type="pmcid">PMC4958252</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Paix&#227;o</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rodrigues</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Couto</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Martins</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>de Carvalho</surname><given-names>CCCR</given-names></string-name>, <string-name name-style="western"><surname>Monteiro</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Sansonetty</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Amaral</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Viveiros</surname><given-names>M</given-names></string-name></person-group>. <year>2009</year>. <article-title>Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli</article-title>. <source>J Biol Eng</source><volume>3</volume>:<elocation-id>18</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/1754-1611-3-18</pub-id><pub-id pub-id-type="pmid">19835592</pub-id><pub-id pub-id-type="pmcid">PMC2774284</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pal</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Misra</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Banerjee</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dam</surname><given-names>B</given-names></string-name></person-group>. <year>2020</year>. <article-title>Adaptation of ethidium bromide fluorescence assay to monitor activity of efflux pumps in bacterial pure cultures or mixed population from environmental samples</article-title>. <source>J King Saud Univ Sci</source><volume>32</volume>:<fpage>939</fpage>&#8211;<lpage>945</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jksus.2019.06.002</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>CLSI</collab>, <collab>EUCAST</collab></person-group>. <year>2025</year>. <article-title>M100 performance standards for antimicrobial susceptibility testing a CLSI supplement for global application</article-title></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>CLSI</collab>, <collab>EUCAST</collab></person-group>. <year>2024</year>. <article-title>Eucast: AST of bacteria</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://www.eucast.org/ast_of_bacteria" ext-link-type="uri">https://www.eucast.org/ast_of_bacteria</ext-link></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Andrews</surname><given-names>JM</given-names></string-name></person-group>. <year>2001</year>. <article-title>Determination of minimum inhibitory concentrations</article-title>. <source>J Antimicrob Chemother</source><volume>48</volume>:<fpage>5</fpage>&#8211;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/48.suppl_1.5</pub-id><pub-id pub-id-type="pmid">11420333</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sopirala</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Mangino</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Gebreyes</surname><given-names>WA</given-names></string-name>, <string-name name-style="western"><surname>Biller</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bannerman</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Balada-Llasat</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Pancholi</surname><given-names>P</given-names></string-name></person-group>. <year>2010</year>. <article-title>Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii</article-title>. <source>Antimicrob Agents Chemother</source><volume>54</volume>:<fpage>4678</fpage>&#8211;<lpage>4683</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.00497-10</pub-id><pub-id pub-id-type="pmid">20713678</pub-id><pub-id pub-id-type="pmcid">PMC2976112</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bellio</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Fagnani</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Nazzicone</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Celenza</surname><given-names>G</given-names></string-name></person-group>. <year>2021</year>. <article-title>New and simplified method for drug combination studies by checkerboard assay</article-title>. <source>MethodsX</source><volume>8</volume>:<elocation-id>101543</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.mex.2021.101543</pub-id><pub-id pub-id-type="pmid">34754811</pub-id><pub-id pub-id-type="pmcid">PMC8563647</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Alexander</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Guru</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Pradhan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mallick</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mahanandia</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Subudhi</surname><given-names>BB</given-names></string-name>, <string-name name-style="western"><surname>Beuria</surname><given-names>TK</given-names></string-name></person-group>. <year>2020</year>. <article-title>MazEF-rifampicin interaction suggests a mechanism for rifampicin induced inhibition of persisters</article-title>. <source>BMC Mol Cell Biol</source><volume>21</volume>:<elocation-id>73</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12860-020-00316-8</pub-id><pub-id pub-id-type="pmid">33109090</pub-id><pub-id pub-id-type="pmcid">PMC7590665</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mallik</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dodia</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ghosh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Srinivasan</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Good</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Raghav</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Beuria</surname><given-names>TK</given-names></string-name></person-group>. <year>2023</year>. <article-title>FtsE, the nucleotide binding domain of the ABC transporter homolog FtsEX, regulates septal PG synthesis in E. coli</article-title>. <source>Microbiol Spectr</source><volume>11</volume>:<elocation-id>e0286322</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/spectrum.02863-22</pub-id><pub-id pub-id-type="pmid">37014250</pub-id><pub-id pub-id-type="pmcid">PMC10269673</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cannella</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Altomare</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chiaramonte</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Di Bella</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mira</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Russotto</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Pisano</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Guercio</surname><given-names>A</given-names></string-name></person-group>. <year>2019</year>. <article-title>Cytotoxicity evaluation of endodontic pins on L929 cell line</article-title>. <source>Biomed Res Int</source><volume>2019</volume>:<elocation-id>3469525</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2019/3469525</pub-id><pub-id pub-id-type="pmid">31815131</pub-id><pub-id pub-id-type="pmcid">PMC6877943</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Faul</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Erdfelder</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Buchner</surname><given-names>A</given-names></string-name></person-group>. <year>2007</year>. <article-title>G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title>. <source>Behav Res Methods</source><volume>39</volume>:<fpage>175</fpage>&#8211;<lpage>191</lpage>. doi:<pub-id pub-id-type="doi">10.3758/bf03193146</pub-id><pub-id pub-id-type="pmid">17695343</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Terres</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Morrison</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Habicht</surname><given-names>GS</given-names></string-name></person-group>. <year>1968</year>. <article-title>A quantitative difference in the immune response between male and female mice</article-title>. <source>Proc Soc Exp Biol Med</source><volume>127</volume>:<fpage>664</fpage>&#8211;<lpage>667</lpage>. doi:<pub-id pub-id-type="doi">10.3181/00379727-127-32768</pub-id><pub-id pub-id-type="pmid">5651115</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Castleman</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Pokhrel</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Triplett</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Kusewitt</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Elmore</surname><given-names>BO</given-names></string-name>, <string-name name-style="western"><surname>Joyner</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Femling</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Hathaway</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Prossnitz</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>Hall</surname><given-names>PR</given-names></string-name></person-group>. <year>2018</year>. <article-title>Innate sex bias of Staphylococcus aureus skin infection is driven by &#945;-hemolysin</article-title>. <source>J Immunol</source><volume>200</volume>:<fpage>657</fpage>&#8211;<lpage>668</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1700810</pub-id><pub-id pub-id-type="pmid">29222165</pub-id><pub-id pub-id-type="pmcid">PMC5760295</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jirkof</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Bratcher</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Medina</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Strasburg</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ebert</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gaskill</surname><given-names>BN</given-names></string-name></person-group>. <year>2020</year>. <article-title>The effect of group size, age and handling frequency on inter-male aggression in CD 1 mice</article-title>. <source>Sci Rep</source><volume>10</volume>:<elocation-id>2253</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-59012-4</pub-id><pub-id pub-id-type="pmid">32042065</pub-id><pub-id pub-id-type="pmcid">PMC7010790</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weber</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Zidar</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ewaldsson</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Askevik</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ud&#233;n</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Svensk</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>T&#246;rnqvist</surname><given-names>E</given-names></string-name></person-group>. <year>2022</year>. <article-title>Aggression in group-housed male mice: a systematic review</article-title>. <source>Animals (Basel)</source><volume>13</volume>:<fpage>143</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ani13010143</pub-id><pub-id pub-id-type="pmid">36611751</pub-id><pub-id pub-id-type="pmcid">PMC9817818</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Missiakas</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Schneewind</surname><given-names>O</given-names></string-name></person-group>. <year>2014</year>. <article-title>Mouse models for infectious diseases caused by Staphylococcus aureus</article-title>. <source>J Immunol Methods</source><volume>410</volume>:<fpage>88</fpage>&#8211;<lpage>99</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jim.2014.04.007</pub-id><pub-id pub-id-type="pmid">24769066</pub-id><pub-id pub-id-type="pmcid">PMC6211302</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nice</surname><given-names>EC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>W</given-names></string-name></person-group>. <year>2023</year>. <article-title>Sertaconazole-repurposed nanoplatform enhances lung cancer therapy via CD44-targeted drug delivery</article-title>. <source>J Exp Clin Cancer Res</source><volume>42</volume>:<elocation-id>188</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s13046-023-02766-2</pub-id><pub-id pub-id-type="pmid">37507782</pub-id><pub-id pub-id-type="pmcid">PMC10385912</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liebel</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lyte</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Garay</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Babad</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Southall</surname><given-names>MD</given-names></string-name></person-group>. <year>2006</year>. <article-title>Anti-inflammatory and anti-itch activity of sertaconazole nitrate</article-title>. <source>Arch Dermatol Res</source><volume>298</volume>:<fpage>191</fpage>&#8211;<lpage>199</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00403-006-0679-8</pub-id><pub-id pub-id-type="pmid">16868738</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Qin</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>J</given-names></string-name></person-group>. <year>2021</year>. <article-title>Sertaconazole provokes proapoptotic autophagy via stabilizing TRADD in nonsmall cell lung cancer cells</article-title>. <source>MedComm</source><volume>2</volume>:<fpage>821</fpage>&#8211;<lpage>837</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mco2.102</pub-id><pub-id pub-id-type="pmid">34977879</pub-id><pub-id pub-id-type="pmcid">PMC8706745</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hou</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>F</given-names></string-name></person-group>. <year>2014</year>. <article-title>Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo</article-title>. <source>Int J Nanomedicine</source><volume>9</volume>:<fpage>5403</fpage>&#8211;<lpage>5413</lpage>. doi:<pub-id pub-id-type="doi">10.2147/IJN.S71623</pub-id><pub-id pub-id-type="pmid">25473279</pub-id><pub-id pub-id-type="pmcid">PMC4247144</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaul</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Akhir</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shukla</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shafi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Akunuri</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Pawar</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ghouse</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Srinivas</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chopra</surname><given-names>S</given-names></string-name></person-group>. <year>2023</year>. <article-title>Oxiconazole potentiates gentamicin against gentamicin-resistant Staphylococcus aureus in vitro and in vivo</article-title>. <source>Microbiol Spectr</source><volume>11</volume>:<elocation-id>e0503122</elocation-id>. doi:<pub-id pub-id-type="doi">10.1128/spectrum.05031-22</pub-id><pub-id pub-id-type="pmid">37428033</pub-id><pub-id pub-id-type="pmcid">PMC10433863</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Nice</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>C</given-names></string-name></person-group>. <year>2022</year>. <article-title>Repurposing oxiconazole against colorectal cancer via PRDX2-mediated autophagy arrest</article-title>. <source>Int J Biol Sci</source><volume>18</volume>:<fpage>3747</fpage>&#8211;<lpage>3761</lpage>. doi:<pub-id pub-id-type="doi">10.7150/ijbs.70679</pub-id><pub-id pub-id-type="pmid">35813474</pub-id><pub-id pub-id-type="pmcid">PMC9254464</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ogino</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Fujii</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ono</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Maezawa</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hori</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kizu</surname><given-names>J</given-names></string-name></person-group>. <year>2009</year>. <article-title>In vivo and in vitro effects of fluoroquinolones on lipopolysaccharide-induced pro-inflammatory cytokine production</article-title>. <source>J Infect Chemother</source><volume>15</volume>:<fpage>168</fpage>&#8211;<lpage>173</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10156-009-0680-1</pub-id><pub-id pub-id-type="pmid">19554401</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sun</surname><given-names>ZL</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Gibbons</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mu</surname><given-names>Q</given-names></string-name></person-group>. <year>2020</year>. <article-title>Synergism of sophoraflavanone G with norfloxacin against effluxing antibiotic-resistant Staphylococcus aureus</article-title>. <source>Int J Antimicrob Agents</source><volume>56</volume>:<fpage>106098</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106098</pub-id><pub-id pub-id-type="pmid">32707171</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Luxameechanporn</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Blair</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kirtsreesakul</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Thompson</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Naclerio</surname><given-names>RM</given-names></string-name></person-group>. <year>2006</year>. <article-title>The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice</article-title>. <source>Int J Infect Dis</source><volume>10</volume>:<fpage>401</fpage>&#8211;<lpage>406</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ijid.2005.07.007</pub-id><pub-id pub-id-type="pmid">16564192</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Miyazaki</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Miyazaki</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Chaisson</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Bishai</surname><given-names>WR</given-names></string-name></person-group>. <year>1999</year>. <article-title>Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis</article-title>. <source>Antimicrob Agents Chemother</source><volume>43</volume>:<fpage>85</fpage>&#8211;<lpage>89</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.43.1.85</pub-id><pub-id pub-id-type="pmid">9869570</pub-id><pub-id pub-id-type="pmcid">PMC89025</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Golocorbin-Kon</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mikov</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Arafat</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lepojevic</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Mikov</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sahman-Zaimovic</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tomic</surname><given-names>Z</given-names></string-name></person-group>. <year>2009</year>. <article-title>Cefotaxime pharmacokinetics after oral application in the form of 3&#945;,7&#945;-dihydroxy-12-keto-5&#946;-cholanate microvesicles in rat</article-title>. <source>Eur J Drug Metab Pharmacokinet</source><volume>34</volume>:<fpage>31</fpage>&#8211;<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF03191381</pub-id><pub-id pub-id-type="pmid">19462926</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Klastersky</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gaya</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zinner</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Bernard</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Ryff</surname><given-names>J-C</given-names></string-name>, <collab>EORTC International Antimicrobial Therapy Project Group Writing Committee</collab></person-group>. <year>1980</year>. <article-title>Cefotaxime and amikacin: results of in vitro and in vivo studies against Gram-negative bacteria and Staphylococcus aureus. EORTC International Antimicrobial Therapy Project Group</article-title>. <source>J Antimicrob Chemother</source><volume>6</volume>:<fpage>55</fpage>&#8211;<lpage>61</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jac/6.suppl_A.55</pub-id><pub-id pub-id-type="pmid">6252180</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Moine</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Sauve</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Vallee</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bedos</surname><given-names>JP</given-names></string-name>, <string-name name-style="western"><surname>Azoulay-Dupuis</surname><given-names>E</given-names></string-name></person-group>. <year>1997</year>. <article-title>In vivo efficacy of cefotaxime and amoxicillin against penicillin-susceptible, penicillin-resistant and penicillin-cephalosporin-resistant strains of Streptococcus pneumoniae in a mouse pneumonia model</article-title>. <source>Clin Microbiol Infect</source><volume>3</volume>:<fpage>608</fpage>&#8211;<lpage>615</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1469-0691.1997.tb00466.x</pub-id><pub-id pub-id-type="pmid">11864201</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Martins</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>McCusker</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Viveiros</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Couto</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Fanning</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Pag&#232;s</surname><given-names>J-M</given-names></string-name>, <string-name name-style="western"><surname>Amaral</surname><given-names>L</given-names></string-name></person-group>. <year>2013</year>. <article-title>A simple method for assessment of MDR bacteria for over-expressed efflux pumps</article-title>. <source>Open Microbiol J</source><volume>7</volume>:<fpage>72</fpage>&#8211;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.2174/1874285801307010072</pub-id><pub-id pub-id-type="pmid">23589748</pub-id><pub-id pub-id-type="pmcid">PMC3624690</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prasad</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kapoor</surname><given-names>K</given-names></string-name></person-group>. <year>2004</year>. <article-title>Multidrug resistance in yeast Candida</article-title>. <source>Int Rev Cytol</source><volume>242</volume>:<fpage>215</fpage>&#8211;<lpage>248</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0074-7696(04)42005-1</pub-id><pub-id pub-id-type="pmid">15598470</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Novo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Perlmutter</surname><given-names>NG</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname><given-names>RH</given-names></string-name>, <string-name name-style="western"><surname>Shapiro</surname><given-names>HM</given-names></string-name></person-group>. <year>1999</year>. <article-title>Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique</article-title>. <source>Cytometry</source><volume>35</volume>:<fpage>55</fpage>&#8211;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(sici)1097-0320(19990101)35:1&amp;#x0003c;55::aid-cyto8&amp;#x0003e;3.0.co;2-2</pub-id><pub-id pub-id-type="pmid">10554181</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Raqeeb</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Anwar</surname><given-names>M</given-names></string-name></person-group>. <year>2018</year>. <article-title>Characterization of novel antibiotic resistance genes in Staphylococcal aureus</article-title>. <source>J Bacteriol Mycol</source><volume>6</volume>. doi:<pub-id pub-id-type="doi">10.15406/jbmoa.2018.06.00167</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Du</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang-Kan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Neuberger</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>van Veen</surname><given-names>HW</given-names></string-name>, <string-name name-style="western"><surname>Pos</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Piddock</surname><given-names>LJV</given-names></string-name>, <string-name name-style="western"><surname>Luisi</surname><given-names>BF</given-names></string-name></person-group>. <year>2018</year>. <article-title>Multidrug efflux pumps: structure, function and regulation</article-title>. <source>Nat Rev Microbiol</source><volume>16</volume>:<fpage>523</fpage>&#8211;<lpage>539</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41579-018-0048-6</pub-id><pub-id pub-id-type="pmid">30002505</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Joshi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wani</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sharma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Satti</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Koul</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>IA</given-names></string-name>, <string-name name-style="western"><surname>Kumar</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bharate</surname><given-names>SB</given-names></string-name>, <string-name name-style="western"><surname>Vishwakarma</surname><given-names>RA</given-names></string-name></person-group>. <year>2014</year>. <article-title>Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: reversing the resistance against frontline antibacterial drugs</article-title>. <source>Med Chem Commun</source><volume>5</volume>:<fpage>1540</fpage>&#8211;<lpage>1547</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C4MD00196F</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mohan</surname><given-names>A</given-names></string-name></person-group>. <year>2023</year>. <article-title>Berberine as an efflux pump inhibitor against quinolone resistant Staphylococcus aureus</article-title>. <source>J Anim Res</source><volume>13</volume>. doi:<pub-id pub-id-type="doi">10.30954/2277-940X.04.2023.2</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Santos</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Soeiro</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Silvestre</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname><given-names>S</given-names></string-name></person-group>. <year>2023</year>. <article-title>Resveratrol as an inhibitor of the NorA efflux pump and resistance modulator in Staphylococcus aureus</article-title>. <source>Antibiotics (Basel)</source><volume>12</volume>:<elocation-id>1168</elocation-id>. doi:<pub-id pub-id-type="doi">10.3390/antibiotics12071168</pub-id><pub-id pub-id-type="pmid">37508264</pub-id><pub-id pub-id-type="pmcid">PMC10376492</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Inxight Drugs</collab></person-group>. <year>1988</year><source>Oxiconazole</source>. <comment>Available from</comment>: <ext-link xlink:href="https://drugs.ncats.io/drug/C668Q9I33J" ext-link-type="uri">https://drugs.ncats.io/drug/C668Q9I33J</ext-link></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="webpage"><article-title>Oxiconazole nitrate | C18H14Cl4N4O4 | CID 9556529 - PubChem</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/9556529" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/9556529</ext-link></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="webpage"><article-title>Oxistat. Prescribing information</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19828slr009,20209slr005_oxistat_lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19828slr009,20209slr005_oxistat_lbl.pdf</ext-link></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="webpage"><article-title>Drug approval package: Ertaczo (Sertaconazole nitrate) NDA #021385</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-385_Ertaczo.cfm" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-385_Ertaczo.cfm</ext-link></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="webpage"><article-title>Drug approval package</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-385_Ertaczo.cfm" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-385_Ertaczo.cfm</ext-link></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="webpage"><article-title>Sertaconazole nitrate</article-title>. <comment>Available from</comment>: <ext-link xlink:href="https://drugs.ncats.io/drug/1DV05410M5" ext-link-type="uri">https://drugs.ncats.io/drug/1DV05410M5</ext-link>. <comment>Retrieved</comment><date-in-citation>07 Feb 2025</date-in-citation>.</mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chayachinda</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Thamkhantho</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rekhawasin</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Klerdklinhom</surname><given-names>C</given-names></string-name></person-group>. <year>2024</year>. <article-title>Sertaconazole 300 mg versus clotrimazole 500 mg vaginal suppository for treating pregnant women with acute vaginal candidiasis: a double-blinded, randomized trial</article-title>. <source>BMC Pregnancy Childbirth</source><volume>24</volume>:<elocation-id>235</elocation-id>. doi:<pub-id pub-id-type="doi">10.1186/s12884-024-06440-z</pub-id><pub-id pub-id-type="pmid">38575932</pub-id><pub-id pub-id-type="pmcid">PMC10993551</pub-id></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>